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SUMMARY 
Systemic sclerosis (SSc) is a rare, clinically heterogeneous, severe multisystem disorder 
characterised by autoimmunity, fibrosis and vasculopathy [Rodnan et al., 1979; Gabrielli et al., 
2009]. It is one of the most disabling and disfiguring diseases among the systemic diseases and 
compared to other rheumatic diseases, SSc is associated with a high loss of life expectancy [Mok 
et al., 2011].  
Raynaud's phenomenon (RP) as an abnormality of the microcirculation is the initial and 
heralding symptom of SSc in over 95% of patients. Skin sclerosis and internal organ involvement 
then mostly manifest with a variable temporal interval after the onset of RP [Walker et al., 2007; 
Varga et al., 2012]. Aside from the skin, multiple organ systems can be damaged by fibrotic 
and/or vascular complications including the gastrointestinal tract, the pulmonary parenchyma 
and circulation, the heart, kidney and the joints [Medsger, 1997; Gabrielli et al., 2009]. Although 
skin fibrosis is the cardinal feature of the disease, the progressive deterioration of internal 
organs determines the clinical outcome [Walker et al., 2007; Domsic et al., 2014; Nihtyanova 
et al., 2014]. 
The aims of this thesis are (1) to map the time after disease onset in terms of RP to the onset 
of organ manifestations in SSc and to identify predictors of an early onset of manifestations; (2) 
to assess the effect of smoking on the manifestation and worsening of SSc organ manifestations 
and (3) to assess the level of functional ability and to identify factors associated with disability. 
This thesis is based on the largest worldwide database for SSc, the European Scleroderma Trials 
and Research group (EUSTAR) registry. By today, more than 15,000 SSc patients are followed 
prospectively in more than 200 expert centres within the EUSTAR network.  
We found that organ manifestations exhibit rapid kinetics early after the onset of RP, implying 
that there is only a short ‘window of opportunity’ to prevent incident organ damage. 
Furthermore, in every organ system, half of all organ manifestations become evident rather 
early in the disease, i.e. within the first two years. This implies that severe complications, for 
instance pulmonary hypertension and interstitial lung disease, are not restricted to late disease. 
Risk factors, such as the SSc subtype, autoantibody profile and the patient's sex do modify the 
cumulative incidences of the organ manifestations but do not substantially modify the steep 
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increase in organ complication rates during the first two years after RP onset. These results are 
of great importance for clinicians, who need to counsel, risk stratify and treat SSc patients early 
on after the diagnosis. Furthermore, the findings are of great significance for the design of 
therapeutics aimed to ‘widen’ the still very narrow ‘window of opportunity’. 
We demonstrated that the known adverse effect of smoking on the bronchial airways and 
alveoli is also observed in SSc patients. However, we did not observe robust adverse effects of 
smoking on the progression of SSc-specific pulmonary or cutaneous manifestations. This finding 
argues against a major role of tobacco-associated free radicals, vasoconstrictor and 
immunomodulatory effects in the pathogenesis of SSc vasculopathy and fibrosis. 
Regarding the functional ability, we found that there is a major difference between the factors 
driving patient perceived levels of disability and those emphasized by physicians in their disease 
evaluation. The patients perceive dyspnoea, gastrointestinal symptoms, pain, muscle weakness 
and the presence of digital ulcers as the main factors driving their level of disability. These 
results that objective disease severity measures as assessed by the physicians do not correlate 
with patient-perceived disability indicate that the many and multi-faced aetiologies of disability 
and quality of life in SSc are poorly understood and are therefore a clarion call to further 
research.  
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1. INTRODUCTION AND BACKGROUND 
1.1 GENERAL INTRODUCTION 
Systemic slcerosis (SSc; also called scleroderma) is a rare, chronic, connective tissue disorder 
affecting the skin as well as internal organs. SSc is characterised by three hallmarks: (1) a 
vascular microangiopathy, (2) a disorder of fibroblast function that enhances the synthesis of 
extracellular matrix and collagen, eventually leading to the characteristic skin thickening and 
fibrosis of visceral organs, and (3) some ill-defined immunological dysfunction, leading to the 
presence of diagnostically relevant SSc-related autoantibodies in the patients’ circulation; in 
particular anticentromere (ACA), anti-topoisomerase (anti-Scl-70) and anti-RNA polymerase III 
(anti-RNAP-III) autoantibodies [Giordano et al., 1986; Medsger, 1997; Steen, 1998; Wollheim, 
2005; Gabrielli et al., 2009; Hudson et al., 2010]. A striking feature of SSc is the heterogeneity 
and the large variability in organ involvement, disease severity, the speed of disease 
progression, and survival between patients. 
Among the different immune-mediated rheumatic diseases, SSc can be one of the most 
disabling and disfiguring diseases. Compared to other rheumatic diseases, SSc is additionally 
associated with the highest loss of life expectancy amounting to more than 30 years in female 
patients and 16 years in male patients [Mok et al., 2011]. 
The aetiology and pathogenesis of SSc are complex, and the exact nature of the events 
underlying the development of the disease is still not fully understood [Abraham et al., 2007, 
2009]. Vascular and immunological processes are of central importance to the pathogenesis of 
SSc. However, the initial triggers and how initial events subsequently amplify and facilitate the 
development of the fibrosis and vasculopathy remains unclear [Piela-Smith et al., 1994; Denton 
et al., 1996]. 
SSc can be subdivided into limited cutaneous and diffuse cutaneous SSc. This diagnosis differs 
on the basis of the extent of skin fibrosis on the patients’ bodies, or into SSc sine scleroderma 
if the patients have no detectable skin fibrosis [LeRoy et al., 1988]. The SSc-specific 
autoantibodies are strong predictors of the patterns of organ involvements as well as disease 
outcome [Steen, 2005; Nihtyanova et al., 2010]. 
DESSCIPHERING SYSTEMIC SCLEROSIS 
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Although skin fibrosis is the cardinal feature of the disease, the progressive deterioration of 
internal organs determines the clinical outcome [Walker et al., 2007; Domsic et al., 2014; 
Nihtyanova et al., 2014]. The frequency and severity of manifestations partly depend on the 
subtype, and the autoantibody profile of the patients. However, patients suffer most frequently 
from Raynaud’s phenomenon (RP), skin, gastrointestinal (GI) and musculoskeletal involvements 
and fatigue [Walker et al., 2007; Lóránd et al., 2014; Shreiner et al., 2016]. Other frequent 
manifestations include digital ulcers (DUs), interstitial lung disease (ILD), pulmonary 
hypertension (PH), cardiac disease and renal crisis [Kahan et al., 2009; Lambova et al., 2010; 
Wells et al., 2015; Hughes et al., 2017].  
In general, SSc is a progressive disease. The disease course and the speed of progression, 
however, varies with disease subtype and also with the presence and severity of manifestations 
early on in the disease [Nihtyanova et al., 2014; Avouac et al., 2016; Wu et al., 2018]. Treating 
SSc patients is still a challenge, and there is no curative treatment. Hence, treatment 
recommendations focus on individual organ manifestations [Kowal-Bielecka et al., 2017]. 
Autologous haematopoietic stem cell transplantation is at present the only disease-modifying 
strategy for the prevention of organ worsening, the improvement of skin and pulmonary 
function, consequently improving survival [van Laar et al., 2014; Sullivan, Goldmuntz, et al., 
2018; Walker et al., 2018]. 
 
1.2 EPIDEMIOLOGY  
SSc is a rare disease, and population-based studies on SSc are relatively sparse. As it is the case 
in all connective tissue diseases, SSc is more prevalent in women than in men with estimated 
ratios mostly ranging between 3:1 and 6:1. However, the disease is more severe in male 
patients  [Clements et al., 2003; Chifflot et al., 2008; Bernatsky et al., 2009; Gabrielli et al., 2009; 
Elhai et al., 2016]. The onset of SSc peaks between the ages of 35 and 65 years; the average 
age of onset varies with sex and race [Mayes, 1997; Mayes et al., 2003; Chifflot et al., 2008]. 
Prevalence estimates also vary considerably from study to study mostly ranging between 50 to 
300 per million [Medsger Jr. et al., 1971; Silman et al., 1988; Arnett et al., 2001; Roberts-
Thomson et al., 2001; Mayes et al., 2003; Allcock et al., 2004; Le Guern et al., 2004; Chifflot et 
DESSCIPHERING SYSTEMIC SCLEROSIS 
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al., 2008; Nikpour et al., 2010; Kuo et al., 2011; Hoffmann-Vold et al., 2012; Royle et al., 2018]. 
The reported SSc prevalences in the US as well as in Australia are consistently higher than the 
estimates for Europe and Asia [Roberts-Thomson et al., 2001; Mayes et al., 2003; Allcock et al., 
2004; Chifflot et al., 2008; Nikpour et al., 2010; Kuo et al., 2011; Barnes et al., 2012; Hoffmann-
Vold et al., 2012; Royle et al., 2018]. High prevalences of SSc are found in some native American 
groups, i.e., the highest ever reported prevalence was found in full-blood Choctaw Indian (4690 
per million) [Arnett et al., 1996]. 
Incidence estimates for SSc also vary considerably between studies, ranging from around 4 to 
23 per million person-years depending on the population [Medsger Jr. et al., 1971; Steen, 
Oddis, et al., 1997; Mayes et al., 2003; Chifflot et al., 2008]. There is an ongoing discussion 
regarding whether the incidence has been increasing during the last decades despitethe lack 
of robust evidence for this [Chifflot et al., 2008; Nikpour et al., 2010; Royle et al., 2018]. 
The considerable variation in the prevalence and incidence estimates might be partially 
reflecting the different classification criteria used in the studies. Additionally, this may also be 
due to differences in case ascertainment methodologies and therefore case completeness as 
well as greater disease awareness in some areas. These differences might also be true 
population differences caused by the populations’ genetic background or environmental 
exposures, but also by the populations’ demographic structure. 
Several risk factors were reported to be associated with SSc development including genetic 
factors, race, age, sex, and environmental factors. Some of these factors are not only associated 
with SSc development but also with more severe disease. For example, African Americans have 
continuously been reported to have higher age and sex-specific incidence rates than whites, in 
some studies up to twice as high  [Laing et al., 1997; Mayes et al., 2003]. However, African 
Americans do not only develop SSc more frequently, but they also suffer from more severe 
disease [Steen, Oddis, et al., 1997; Greidinger et al., 1998; Beall et al., 2007; Steen et al., 2012; 
Jaeger et al., 2018]. 
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1.3 MANIFESTATIONS 
The systemic manifestations of SSc are diverse. Although skin fibrosis is the hallmark feature of 
SSc, multiple organ systems can be affected by fibrotic and/or vascular complications including 
the GI tract, the pulmonary parenchyma, the circulatory system, the heart, kidney and joints 
(Figure 1) [Medsger, 1997; Gabrielli et al., 2009; Allanore et al., 2015; Denton et al., 2017]. 
 
 





The most common manifestations result from abnormalities in the microcirculation, with RP 
being most notable. RP is classically seen as a reversible vasospasm caused by functional 
changes in the small digital arteries of the feet and predominantly the hands and is triggered 
primarily by cold or stress [Wigley et al., 1996; Sunderkötter et al., 2006; Herrick, 2012]. RP is 
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the initial and heralding symptom of SSc in more than 90% of patients [Sunderkötter et al., 
2006]. Skin sclerosis and internal organ involvement mostly manifest with a variable temporal 
interval after the onset of RP (Figure 2) [Walker et al., 2007; Allanore et al., 2015]. There is, 
however, a paucity of reliable, robust and evidence-based data on the temporal evolution of 
skin manifestations as well as on the temporal evolution of the internal organ manifestations 
as until now the knowledge on this timing (such as Figure 2 [Varga et al., 2012]) has only 
experienced-based. There is also a lack of knowledge of factors associated with faster 
development of these manifestations. As the various SSc manifestations constitute a crucial 
cause of morbidity and mortality, sound knowledge on when to expect the manifestations to 
occur is essential for physicians to risk stratify and counsel the patients early on after diagnosis. 
Additionally, such estimates of the patient’s future trajectory of organ involvement are 
essential for the design of clinical trials aimed at altering the natural course of the disease. 
Therefore, one goal of this thesis was to longitudinally map the onset and identify risk factors 
for skin sclerosis and other SSc manifestations (Aim 1; Article 1 and 2). 
 
 
Figure 2. Usual timing of organ involvement according to clinical experience (adapted from 
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As mentioned above, SSc is commonly divided into two main subtypes, namely limited 
cutaneous SSc and diffuse cutaneous SSc [LeRoy et al., 1988]. In the limited cutaneous form, 
skin thickening is restricted to the hands, lower arms and the face. In the diffuse cutaneous 
form, the skin also thickens in body areas proximal to the elbows and knees [Gabrielli et al., 
2009]. Patients without skin fibrosis, i.e. ‘SSc sine scleroderma’, present with serological and 
clinical signs of SSc without detectable skin involvement [Hachulla et al., 2011; Sullivan, Majhail, 
et al., 2018]. Patients with limited or diffuse SSc have distinct patterns of organ pathology, 
speed of disease progression and outcomes (Figure 2 and Table 1). However, not all patients fit 
neatly into one of the subtypes [Varga et al., 2014]. 
 
 
Table 1. Clinical subsets in SSc (adapted from [Allanore et al., 2015]). 
 









• Distal skin fibrosis, 
sclerodactyly, telangiectasia, 
and calcinosis cutis may be 
prominent 
• Severe interstitial lung 
disease and scleroderma 
renal crisis are very rare  
ACA 
• Raynaud phenomenon 
may precede other 
manifestations 
• Slow progression with late 
development of pulmonary 





• Proximal skin fibrosis up to 
elbows and knees, including 
trunk 
• Tendon friction rubs may 
be present  
Anti-Scl-70 and 
Anti-RNAP-III  
• Rapidly progressive skin 
fibrosis 
• Early occurrence of renal, 










abnormalities, and PAH  
 
 
Most SSc patients have highly specific circulating autoantibodies [Nihtyanova et al., 2010]. The 
three most frequent types of antinuclear autoantibodies associated with SSc are ACA, anti-Scl-
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70, and anti-RNAP-III autoantibodies. These autoantibodies are considered to be highly specific 
for SSc and are generally present exclusive of each other [Steen, 2005; Nihtyanova et al., 2010; 
Heijnen et al., 2013]. The type of autoantibody is strongly associated with distinct clinical 
manifestations, organ complications and risk of mortality (Table 1) [Ho et al., 2003; Ioannidis et 
al., 2005]. 
Anti-Scl-70 and Anti-RNAP-III autoantibodies are generally associated with diffuse cutaneous 
SSc [Gabrielli et al., 2009; Allanore et al., 2015]. Furthermore, anti-Scl-70 is associated with an 
increased risk of severe ILD, DU, and hand disability while anti-RNAP-III positivity is associated 
with rapidly progressing skin involvement, an increased risk of scleroderma renal crisis (SRC) 
and an increased risk of malignancies [Shah et al., 2010, 2015; Nguyen et al., 2011; Nikpour et 
al., 2011; Moinzadeh et al., 2014; Denton et al., 2017]. In contrast, ACA is usually associated 
with limited cutaneous SSc and an increased risk to develop PAH [Steen, 2005]. 
The preventable and modifiable risk factor, smoking, has been established as an important 
environmental contributor to other autoimmune diseases such as rheumatoid arthritis [Saag et 
al., 1997; Källberg et al., 2011; Di Giuseppe et al., 2014]. Unlike its role in rheumatoid arthritis, 
smoking does not confer a risk for development of SSc [Chaudhary et al., 2011]. However, the 
association between smoking and SSc disease manifestations remains controversial as robust 
data with regards to a role of cigarette smoking exposure in the severity and the progression 
of SSc are scarce and limited to smaller, often cross-sectional studies. These results are of great 
importance firstly to clinicians who counsel and manage systemic sclerosis patients, and also 
to patients wondering about the effect of the modifiable risk factor smoking on their disease 
outcome. Therefore, one aim of this thesis was to rigorously assess this possible association 
between smoking and disease manifestations (Aim 2; Article 3).  
 
Skin Involvement 
Despite the heterogeneous clinical presentation of SSc, skin involvement is the cardinal feature 
of SSc and usually first develops distally in the fingers and hands [Krieg et al., 2006]. Many 
patients initially experience non-pitting oedema of the fingers, erythema, and pruritus prior to 
the development of skin induration. Following this, the skin becomes firm, hard and tight, 
adhering to deeper structures and limiting movement. The thickening of the skin is caused by 
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an overproduction of collagen and extracellular matrix in the dermis and by temporary 
oedemata due to microvascular leaks [Clements et al., 2004; Krieg et al., 2006]. Commonly, skin 
thickness tends to increase over time especially in early diffuse SSc and then decreases in later 
stages [Denton et al., 2017]. Skin sclerosis is present in almost all SSc patients; only less than 
5% of patients have no skin sclerosis, i.e., SSc sine scleroderma [Krieg et al., 2006; Denton et 
al., 2017]. 
Whereas skin fibrosis per se is not causing increased mortality, severe or rapidly progressive 
skin involvement is associated with internal organ involvement leading to increased mortality 
[Shand et al., 2007; Denton et al., 2017]. Furthermore, skin involvement causes a substantial 
burden on patients’ quality of life [Hudson et al., 2009].   
Skin thickening is most commonly quantified using the modified Rodnan skin score (mRSS) 
[Clements et al., 1993; Pope et al., 1995; Furst et al., 1998]. The skin thickness at 17 anatomic 
sites is rated on a scale from 0 (normal) to 3 (most severe). The total skin score is the sum of 
the skin thicknesses at the 17 body sites with a possible range from 0 to 51 with higher values 
indicating a greater extent and severity of skin thickening [Krieg et al., 2006]. The mRSS score 
has been validated as a reliable outcome measure and has demonstrated large effect sizes and 
sensitivity to change [Clements et al., 1995; Kaldas et al., 2009; Kumánovics et al., 2017]. 
 
Digital Ulcers 
DUs are a prevalent, external manifestation of vasculopathy [Steen et al., 2009]. In around 50% 
of SSc patients, DUs occur at some time during the disease [Hachulla et al., 2007; Steen et al., 
2009; Khimdas et al., 2011] while around 10% to 15% of all SSc patients have ‘current’ DUs 
[Khimdas et al., 2011; Ennis et al., 2013]. DUs most commonly occur on the fingers, but also on 
the toes, causing local pain and often taking months to heal [Amanzi et al., 2010; Hughes et al., 
2017]. DUs are associated with much of the morbidity associated with SSc and predict a worse 
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Gastrointestinal Involvement 
The GI tract is the most frequently affected internal organ system with complications varying 
in severity and clinical effect. Approximately 90% of SSc patients suffer from GI manifestations 
with the upper and lower tracts being commonly affected largely owing to a disordered 
gastrointestinal mobility [Sandmeier et al.; Walker et al., 2007; Schmeiser et al., 2012; Shreiner 
et al., 2016]. The most common symptoms include gastroesophageal reflux, bloating, 
distension, constipation or diarrhoea, and anorectal incontinence [Shreiner et al., 2016; Denton 
et al., 2017]. GI involvement may lead to severe malnutrition as well as weight loss which then 
carries a significant amount of morbidity in SSc [Omair et al., 2012; Bharadwaj et al., 2015; 
Codullo et al., 2015]. 
 
Cardiac Involvement 
Heart involvement in SSc is often clinically occult, and therefore its prevalence is probably 
largely underestimated. Any cardiac structure can be affected, and symptoms depend on the 
location of the cardiac pathologies [Kahan et al., 2009; Boueiz et al., 2010; Meune et al., 2010; 
Parks et al., 2014]. Clinical evident cardiac involvement has a poor prognosis as around a third 
of SSc-related deaths have a cardiac origin [Desai et al., 2011; Elhai et al., 2017]. Patients of 
both subsets, limited and diffuse, are at risk for cardiac pathologies; however, patients with 




Pulmonary manifestations are the leading cause of SSc-related deaths. The most common types 
of lung diseases in SSc are PH and ILD. The two manifestations have different pathogeneses, 
clinical features, and predictors. 
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Pulmonary Hypertension 
PH is a frequent and severe SSc manifestation that occurs mainly in three forms: (1) isolated 
PAH, (2) PH secondary to ILD and (3) PH secondary to chronic left-heart disease [Launay et al., 
2017]. PAH is a disease of the small pulmonary arteries and is characterised by a progressive 
increase in pulmonary vascular resistance, right ventricular failure and ultimately death [Launay 
et al., 2007]. The prevalence of PAH in SSc is around 5-15% [Mukerjee et al., 2003; Walker et 
al., 2007; Avouac et al., 2010; Yang et al., 2013]. Despite advances in the treatment arsenal, the 
prognosis of PAH patients is still poor with a median survival time of 3 years [Lefevre et al., 
2013]. PAH is typically seen in patients with longstanding disease and is more common in 
patients with limited SSc than in patients with diffuse disease [Shahane, 2013; Launay et al., 
2017]. 
 
Interstitial Lung Disease 
SSc-related ILD is another severe, potentially fatal complication of SSc. In fact, interstitial lung 
involvement is the most frequent cause of death in SSc with around 35% of all SSc related 
deaths directly attributable to it [Steen et al., 2007; Tyndall et al., 2010]. Progressive fibrosis of 
the lung is an SSc hallmark and results from an excess synthesis and deposition of collagen 
[Schoenfeld et al., 2015].  
The spectrum of ILD severity ranges from non-progressive sub-clinical ILD to major pulmonary 
fibrosis and inflammation progressing ultimately to respiratory failure and death [Khanna et al., 
2010, 2011; Solomon et al., 2013; Wells et al., 2015]. ILD is present in around 80% of SSc 
patients but only around a third of patients develop progressive ILD [Khanna et al., 2015; 
Denton et al., 2017]. SSc-ILD is more prevalent in diffuse patients as it is in anti-Scl70 positive 
patients,and patients of African ancestry have a higher prevalence, incidence, and severity of 
SSc-ILD [Walker et al., 2007; Steen et al., 2012; Gelber et al., 2013; Jaeger et al., 2018]. Older 
age and a low FVC early on in the disease are associated with progression of ILD as well as death 
due to ILD [Winstone et al., 2014; Schoenfeld et al., 2015]. 
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Renal crisis 
Scleroderma renal crisis occurs in around 5-15% of SSc patients and is characterised by the 
sudden development of hypertension, thrombotic microangiopathy and renal failure [Steen, 
1996; Muangchan et al., 2013; Woodworth et al., 2018]. Scleroderma renal crisis is most 
commonly present in patients with rapidly progressive diffuse SSc [Muangchan et al., 2013; 
Allanore et al., 2015]. Additionally, anti-RNAP-III positivity is strongly associated with renal crisis 
development as is corticosteroid therapy on medium to high dosage [DeMarco et al., 2002; 
Nguyen et al., 2010; Nikpour et al., 2011; Iudici et al., 2013].  
While scleroderma renal crisis has been the most frequent cause of SSc-related mortality in the 
last century, it has become considerably less frequent during the last years possibly due to 
earlier diagnosis and/or aggressive use of preventive angiotensin-converting-enzyme inhibitors 
(Figure 3) [Steen et al., 2007]. 
 
 
Figure 3. Changes in causes of SSc‐related deaths between 1972 and 2001 (from [Steen et al., 
2007])  
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1.4 SURVIVAL 
SSc has a profound impact on the life expectancy and continues to carry one of the highest risks 
of mortality of all connective tissue diseases [Elhai et al., 2012; Rubio-Rivas et al., 2014]. The 
reported mortality rates differ significantly between studies, though when pooled in meta-
analyses the standardised mortality rates are around 2.7 to 3.5 compared to the general 
population [Elhai et al., 2012; Rubio-Rivas et al., 2014]. The average life expectancy of SSc 
patients is around 16 to 34 years less than in the general age, and sex-matched population 
[Mok et al., 2011; Elhai et al., 2012; Nikpour et al., 2014]. 
The overall cumulative survival estimates are around 80% to 90% for a 5-year survival measured 
from the onset of RP and 60% to 80% for a 10-year survival [Lee et al., 1992; Hesselstrand et 
al., 1998; Arias-Nuñez et al., 2008; Czirják et al., 2008; Rubio-Rivas et al., 2014]. However, the 
survival rates of patients vary greatly according to the extent of the skin involvement. The 10-
year survival estimates in patients with diffuse SSc ranges from below 50% to around 70% 
whereas in patients with limited SSc the estimates are around 80% [Hesselstrand et al., 1998; 
Arias-Nuñez et al., 2008; Czirják et al., 2008; Rubio-Rivas et al., 2014]. Additionally, the 
distribution and severity of internal organ involvement, anti-Scl70 positivity, older age at onset 
and male sex are associated with increased mortality [Hesselstrand et al., 1998; Arias-Nuñez et 
al., 2008; Czirják et al., 2008; Tyndall et al., 2010; Hissaria, Lester, et al., 2011; Rubio-Rivas et 
al., 2014; Elhai et al., 2017]. 
The causes of SSc-related deaths have changed over the past decades after the introduction of 
new therapies. The number of deaths related to SRC, once the predominant cause of death, 
has significantly reduced and nowadays pulmonary involvement, i.e., ILD and PH, is the leading 
cause of death (Figure 3) [Steen et al., 2007]. 
 
1.5 QUALITY OF LIFE AND FUNCTIONAL ABILITY 
SSc, especially due to its chronicity and multi-organ manifestations, greatly affects the patients’ 
physical and psychological functioning, and impairs their ability to participate in work and social 
activities [Johnson et al., 2006; Hudson et al., 2009; Sekhon et al., 2010; Almeida et al., 2015; 
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Frantz et al., 2016]. Excluding stem cell transplantation, the treatment arsenal holds no 
definitive therapy or ability to change the disease profile. Therefore, one of the most important 
goals of care is to alleviate symptoms, disability, and to improve the health-related quality of 
life (QoL) and functional ability [Saketkoo, 2017; Walker et al., 2018].   
Various studies have identified SSc-related symptoms affecting the patients’ QoL, functional 
ability and mental well-being, such as pain, GI symptoms, pruritus, fatigue, sleep problems, 
work disability and sexual dysfunction [Wagner et al., 2000; Schieir et al., 2010; Kwakkenbos et 
al., 2015; Jaeger et al., 2016; Nakayama et al., 2016; Racine et al., 2016]. However, due to the 
rarity of the disease, most of these studies have a limited sample size and focus on sub-
populations, for example only patients with DUs or patients with PH [Chow et al., 2008; 
Strickland et al., 2012; Guillevin et al., 2013; Lumetti et al., 2015].  
In clinical practice, the management of SSc patients is challenging. The physicians’ main 
attention while caring for SSc patients is usually focused on objective measures of disease 
status and ultimately the survival of the patients. These measures may, however, not reflect 
the patients’ experiences with the disease and the self-perceived impacts on QoL and 
functional capacity. Given the chronicity of the disease and the broad spectrum of 
manifestations with multiple organs involved, it is critical to consider the patients’ perspectives. 
Therefore, one aim of this thesis was to analyse functional disability in a large and unselected 
cohort of SSc patients and to identify factors contributing to impairment as perceived by the 
patients (Aim 3; Article 4). 
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2. AIMS OF THE THESIS 
This thesis aims to evaluate various organ manifestations in SSc and to identify possible risk 
factors for the severity of organ manifestations, the time to onset of these organ manifestations 
and their speed of worsening. In addition to evaluating these more clinical and objective 
measures of disease status, a further aim is to assess disease-related factors which the patients 
perceive as most burdensome and disabling in their life.  
 
The specific research aims are: 
 
Aim 1 To map the incidence and predictors of cutaneous, pulmonary, cardiac, 
gastrointestinal and renal involvement in the early course of SSc (Article 1, Article 
2). 
 
Aim 2 To assess the effects of smoking on the disease presentation as well as the on the 
speed of worsening of organ manifestations, namely lung involvement, skin 
involvement and DU in SSc (Article 3).  
 
Aim 3 To assess the level of functional disability in a large cohort of SSc patients, and to 
identify patient perceived factors contributing to functional impairment (Article 4). 
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3. PATIENTS AND METHODS 
3.1. PATIENT REGISTRIES 
This thesis is entirely based within the European Scleroderma Trials and Research group 
(EUSTAR) registry and within the DeSScipher study, a ´top-on` project of the EUSTAR group. 
 
3.1.1. EUSTAR Registry  
The EUSTAR group was founded in 2004 under the auspices of the European League against 
Rheumatism (EULAR) to foster the awareness, understanding, and research on SSc [Tyndall et 
al., 2005; EUSTAR, 2018].  
One of the integral parts of the EUSTAR group was the development of a ‘minimal essential 
data set (MEDS)’ to harmonise data collection across centres caring for SSc patients, therefore, 
allowing to longitudinally follow large patient groups which in terms allows sufficient sample 
sizes to answer an array of research questions (Figure 4). Due to the rare nature of the disease, 
this would not have been be possible without a large international collaboration.  
The EUSTAR database was launched in 2004 with the 'minimal essential data set' and has been 
significantly extended over the last years [Tyndall et al., 2005; Galluccio et al., 2011; EUSTAR, 
2018]. The EUSTAR network is mainly, however not exclusively, Europe-based and the database 
is by far the largest worldwide following SSc patients. Today, the network consists of more than 
200 centres caring and prospectively and longitudinally documenting more than 15,000 SSc 
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3.1.2. DeSScipher Study 
DeSScipher is the acronym for ‘to decipher the optimal management of systemic sclerosis’. It 
was a large international EU-funded research project, mainly consisting of five non-
interventional, observational trials. The DeSScipher project aimed to improve the treatment 
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strategies for SSc and therefore improve the quality of everyday life for SSc patients. 
Specifically, the DeSScipher project aimed to evaluate the prevention and treatment of DUs 
(observational trial 1), the improvement of hand dysfunction by arthritis (observational trial 2), 
the prevention and treatment of ILD (observational trial 3), the development and prevention 
of PH (observational trial 4) and the development and prevention of severe heart disease 
(observational trial 5) [The DeSScipher Project, 2013]. An additional DeSScipher aim was to 
identify predictors of functional disability in SSc (Aim 3; Article 4).  
The DeSScipher study was designed as a ‘top-on’ study of the EUSTAR database, i.e., the 
database was extended in a modular way so that EUSTAR centres also taking part in the 
DeSScipher project had access to the DeSScipher module of the database additionally to the 
EUSTAR part, whereas the other EUSTAR centres did not. DeSScipher patients as such were not 
selected for any specific organ manifestations, as the DeSScipher patient cohort consisted 
solely of EUSTAR patients being followed at DeSScipher centres during the DeSScipher project 
regardless of organ manifestations and eligibility into any of the DeSScipher observational trials. 
Please see the DeSScipher study’s website for the DeSScipher consortium centres and 
DeSScipher contributing centres [The DeSScipher Project, 2013]. 
 
3.2. INCLUSION CRITERIA INTO EUSTAR AND DESSCIPHER 
Initially, all SSc patients fulfilling the 1980 SSc classification criteria were included in EUSTAR 
[Masi et al., 1980]. In 2013, the new 2013 ACR/EULAR SSc classification criteria were 
implemented in the database and patients fulfilling either were enrolled [van den Hoogen et 
al., 2013]. As DeSScipher was a ‘top-on’ of EUSTAR, the same inclusion criteria applied. 
 
3.3. DATA COLLECTION, MANAGEMENT, AND MONITORING 
Any SSc patients followed in one of the ‘EUSTAR centres’ were (and still are) invited to take part 
in EUSTAR. The same applies to ´DeSScipher centres`. All patient-specific information entered 
into the EUSTAR database was pseudonymised using Soundex. The Soundex is an algorithm in 
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which the family name and first name of the patient is used to create a string [Porta et al., 
2008]. The Soundex has the advantage that the care teams at the centres can search for their 
patients' data by their names, i.e., name to Soundex direction, but not the other way around, 
i.e., Soundex to name direction. The Soundex is also helpful in detecting duplicate patient 
entries. 
Initially, data were collected on paper in each centre, faxed to the EUSTAR office and entered 
into an access database. In 2007, an online, browser-based database was established with an 
intuitive, easy-to-use web interface and the original data collected, i.e., the MEDS, were greatly 
extended [Tyndall et al., 2005; Galluccio et al., 2011; EUSTAR, 2018]. Since then, data are 
recorded locally within each centre.  
Regular EUSTAR courses are offered to train physicians caring for SSc patients and therefore 
also improve EUSTAR’s data quality [Czirják et al., 2007]. In July 2013, an updated data model 
was implemented including extensive plausibility, validity and range checks to enhance data 
quality and reliability. Data quality within the DeSScipher project was additionally improved by 
off- and onsite data monitoring. 
 
3.4. COLLECTED DATA, OUTCOME MEASURES AND COVARIATES 
In the EUSTAR database, data are collected in a standardised form and are structured into 
patient’s history, physical examination, tests and functions, lab results and medication. Data 
collected include: 
 Patient’s History 
Date of birth, sex, RP onset and current RP, date of the first non-RP SSc manifestation, 
GI symptoms, presence of dyspnoea and previous renal crisis; 
 Physical Examination 
Fulfillment of the classification criteria for SSc, skin involvement, the presence of DUs 
and pitting scars as well as the presence of telangiectasia, tendon friction rubs, muscle 
atrophy and weakness and joint contractures and synovitis; 
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 Tests and Function 
Results of electrocardiography, echocardiography, right heart catheterisation, lung 
function test, x-ray and high-resolution computed tomography (HRCT) results; 
 Lab Result 
SSc-related autoantibodies, creatinine kinase elevation, hypocomplementaemia, 
proteinuria. 
In the course of the 2013 database update, also questions on smoking status (current, ex, 
never) and smoking intensity (pack years) as well as the time since smoking cessation and the 
duration of smoking were also implemented. As part of the DeSScipher project the Scleroderma 
Health Assessment Questionnaire (SHAQ), a patient-reported outcome (PRO) measure 
assessing functional ability, was implemented. 
EUSTAR and DeSScipher are strictly observational, however yearly patient visits are 
encouraged. 
 
3.5. STATISTICAL ANALYSES 
For aim 1, i.e. the analysis of the speed of onset of organ manifestations and their predictors, 
we used two main methods: (1) Kaplan-Meier analyses to assess the cumulative probabilities 
of developing disease features as a function of time after RP onset and (2) Cox proportional 
hazards regression analyses to assess the combined effect of potential risk factors.  
For both analyses, the date of the visit at which the organ manifestation was first observed was 
used as the end time, i.e., the incident time point. Manifestations that were already present at 
the first visit were also regarded as incident. If a manifestation was never observed, the date of 
the last follow-up visit was set as the censor time.  
Kaplan-Meier estimates were stratified by sex, age, autoantibody status, and diffuse or limited 
skin involvement and strata were compared with log-rank tests. Cox proportional hazards 
regression analysis was used to assess the combined effect of the a priori defined potential risk 
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factors sex, age, autoantibody status and the extent of skin involvement on disease 
manifestations. 
In aim 2, we assessed the associations of smoking behaviour with (1) the presence and severity 
of disease manifestations and (2) the progression in disease severity with multiple linear and 
logistic regression analyses adjusting for age, sex, time since RP and since first non-RP 
manifestation, antibody status and skin involvement. We analysed the outcome progression 
downscaled to a rate-of-change-per-12-months. We opted for this approach instead of 
assessing the outcome levels at follow-up while adjusting for the baseline levels to avoid 
introducing a bias and also to avoid the possibility of substantially inflating the regression 
coefficient estimates and the introduction of spurious associations [Glymour et al., 2005]. 
Three smoking metrics were modelled separately:  
Model 1 never smoking vs. previous smoking vs. current smoking,  
Model 2 smoking intensity using pack-years:   
never smokers – 0 pack-years,  
light smokers – 0-10 pack-years,  
medium smokers – 10-25 pack-years,  
heavy smokers – >25 pack-years  
Model 3 comprehensive smoking index (CSI).  
The CSI is an index incorporating smoking duration, time since cessation and smoking intensity 
into a single variable [Dietrich et al., 2004; Leffondré et al., 2006]. The CSI depends on two 
parameters: the half-life, i.e., the rate at which the smoking’s impact decays over time, and the 
lag-time, i.e., the delay between smoking and its impact. Both of those parameters are 
estimated separately for each outcome, and hence the CSI is different for each outcome. We 
identified the best combination of estimates of the two parameters for each outcome by 
minimising the Akaike Information Criterion [Akaike, 1974]. 
In aim 3, we assessed the predictors of functional disability as measured by the SHAQ by means 
of univariable and multivariable linear regression analyses. We also assessed the predictors of 
functional disability separately in patients with diffuse and patients with limited SSc. For this, 
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we reduced the model and only included factors that were strong and clinically significant 
predictors of functional disability in the overall patient group or that were defined a priori.  
The minimal clinical important difference (MCID) of the Health Assessment Questionnaire 
(HAQ) is stated to be ≥0.22 [Wells et al., 1993]. As the SHAQ is based on the HAQ and has the 
same range, we also applied this threshold to the SHAQ and we treated a difference of ≥10mm 
as the MCID for the visual analogue scale (VAS) components of the SHAQ [Wells et al., 1993; 
Dworkin et al., 2008; Strand et al., 2011]. 
Like most registries, EUSTAR/DeSScipher also has missing data. To deal with the potential 
problems of missing data, i.e. biased results and loss of precision, we decided to apply multiple 
imputation with chained equations for objectives 2 and 3 after assessing the missingness 
mechanisms, i.e. only for data for which at least the missing at random assumption holds 
[Sterne et al., 2009; White et al., 2010; Carpenter et al., 2013]. Missing covariate values, as well 
as missing outcome values, were imputed 50 times. Missing data of categorical variables were 
either imputed with logistic regression, ordered logistic regression or multinomial logistic 
regression depending on the nature of the variable. We did not transform non-normally 
distributed numerical variables to preserve the possible associations of these variables with the 
other variables in the model. Instead, we used predictive mean matching based on the 20 
nearest neighbours for all non-categorical variables [Little, 1988; Morris et al., 2014]. The 
multiple imputation was carried out using the user-written ice command (Aim 3) and Stata’s 
inbuilt mi command (Aim 2) [Royston, 2005, 2009; Stata Press, 2017].  
All analyses were performed with Stata/IC version 13.1 and 15.1 (StataCorp, College Station, 
Texas, USA). For all aims, standard descriptive analyses were applied.   
More details about the statistical analyses used can be found in the respective articles.  
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4. ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS – WHEN DOES IT START? 
ARTICLE 1: INCIDENCE AND PREDICTORS OF CUTANEOUS MANIFESTATIONS DURING THE EARLY 
COURSE OF SYSTEMIC SCLEROSIS: A 10-YEAR LONGITUDINAL STUDY FROM THE EUSTAR 
DATABASE. 
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ABSTRACT 
Objectives  
To longitudinally map the onset and identify risk factors for skin sclerosis and DU in patients 
with SSc from an early time point after the onset of RP in the EUSTAR cohort. 
Methods 
695 SSc patients with a baseline visit within one year after RP onset were followed in the 
prospective multinational EUSTAR database. During the 10-year observation period, cumulative 
probabilities of cutaneous lesions were assessed with the Kaplan-Meier method. Cox 
proportional hazards regression analysis was used to evaluate risk factors. 
Results 
The median mRSS peaked 1.0 year after RP onset and was 15 points. The 1-year probability to 
develop a mRSS≥2 in at least one area of the arms and legs was 69%, and 25%, respectively. 
Twenty-five percent of patients developed diffuse cutaneous involvement in the first year after 
RP onset. This probability increased to 36% during the subsequent two years. Only 6%of 
patients developed diffuse cutaneous SSc thereafter. The probability to develop DU increased 
to a maximum of 70% at the end of the 10 year observation. The main factors associated with 
diffuse cutaneous SSc were the presence of anti- RNAP-III autoantibodies, followed by anti-Scl-
70 autoantibodies and male sex. The main factors associated with incident DU was the presence 
of anti-Scl-70 autoantibodies.  
Conclusions 
Early after RP onset, cutaneous manifestations exhibit rapid kinetics in SSc. This should be 
accounted for in clinical trials aiming to prevent skin worsening. 
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INTRODUCTION 
SSc is a multisystem autoimmune disorder, characterised by vasculopathy and excessive tissue 
fibrosis [Rodnan et al., 1979; Gabrielli et al., 2009]. Skin sclerosis is a hallmark feature of the 
disease and is most commonly measured with the mRSS by assessing skin thickness in 17 
different body parts [Rodnan et al., 1979; Clements et al., 1995; Kaldas et al., 2009]. Dependent 
on the distribution of skin sclerosis, patients are categorised, at the maximum of extent, as 
having either limited or diffuse skin involvement [LeRoy et al., 1988]. Discrimination between 
limited and diffuse cutaneous SSc is important, as diffuse cutaneous SSc is associated with 
higher morbidity and mortality independent of autoantibody status [Walker et al., 2007]. DU 
are cutaneous lesions caused by obliterative vasculopathy. Both, skin sclerosis and DU have 
proven to highly impact daily living and quality of life [Mouthon et al., 2010; Bérezné et al., 
2011]. 
Several cross-sectional studies suggest that the prevalence of both, skin sclerosis and DU, 
depends on sex, age and autoantibody status [Walker et al., 2007; Sunderkötter et al., 2009; 
Hügle et al., 2011; Khimdas et al., 2011; Manno et al., 2011; Hasegawa et al., 2013; Alba et al., 
2014]. However, only few studies have prospectively investigated the impact of risk factors for 
cutaneous SSc lesions [Perera et al., 2007; Hasegawa et al., 2013]. Some of these studies were 
small, others did not investigate DU incidence, not able to capture the onset of skin sclerosis 
early during the disease course, or able to calculate incidences.  
Given the paucity of pivotal data on the temporal evolution of skin manifestations during the 
early course of SSc, our goal was to analyse the incidence of skin sclerosis and DU in patients 
who developed SSc within one year after the onset of RP.  
By using real-life data from the large multi-centre EUSTAR cohort [Walker et al., 2007], we also 
assessed the skin sclerosis in different body areas, and determined factors associated with an 
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METHODS  
Study population and design 
The architecture of the multinational, prospective EUSTAR Scleroderma Trials and Research 
database has been described elsewhere [Walker et al., 2007; Meier et al., 2012]. In order to be 
able to document clinical data of patients, each participating centre obtained ethical approval 
by its local ethics committee; written informed consent was acquired from each patient 
registered. The demographic and disease characteristics of patients collected between the 
database inauguration in June 2004 and the date of censoring (18th February 2014) were 
exported, provided that the patients were older than 18 years at their first EUSTAR visit and 
fulfilled the 1980 ACR criteria for SSc [Masi et al., 1980]. In order to capture patients early in 
their disease course, i.e. to simulate an inception cohort, the analysis was restricted to patients 
who had their first EUSTAR visit within one year after RP onset.  
Several outcome measures were analysed as a function of time after RP onset: the evolution of 
the mRSS, the presence of skin sclerosis (defined as a mRSS≥2 points at the body area of 
interest), the presence of diffuse cutaneous involvement (defined as a mRSS≥2 points in at least 
one of the 6 skin areas proximal to the elbows and knees, i.e. upper arms, chest, abdomen, 
thighs) and the presence of DU (defined as ulcers distal to, or at the proximal interphalangeal 
joints, and not thought to be due to trauma). The effect of sex, age (dichotomised at the median 




Frequencies and percentages of categorical variables were compared using Pearson's Χ2-tests. 
Means and SD, and for non-normally distributed variables additionally medians and IQR were 
reported; two-group comparisons were performed using Student’s t-tests or Wilcoxon-Mann-
Whitney-tests. 
Using Kaplan-Meier methods we assessed the time to the first diagnosis of the manifestations. 
The date of the visit at which these were first observed was used as the end time. In case the 
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manifestation was already present at the first visit, the date of this first visit was regarded the 
end time. If the manifestation was never observed, the date of the last follow-up visit was 
regarded the censor time. Kaplan-Meier-estimates were compared by log-rank tests and 
incidence rates and their 95% CI were calculated. Cox proportional hazards regression analysis 
was used to assess the combined effect of the potential risk factors sex, age and autoantibody 






At the time of the data export, the EUSTAR database included 9891 patients fulfilling the 
inclusion criteria. Of these, 695 patients had their first EUSTAR visit within one year of RP onset. 
These patients had a median observation time of 2.1 years (IQR 0.7-4.6; mean 3.1 years, SD 
3.0). The patients included in our analysis were approximately 9 years older, had a higher 
baseline mRSS, and more frequently anti-Scl-70 or anti-RNAP-III autoantibodies than the 
patients excluded (Table 2). Furthermore, the percentage of men was significantly higher in the 
group analysed, than in the excluded group. In contrast, DU and ACA were less frequent. 
 
Skin sclerosis by body area 
We first aimed to describe the onset of skin sclerosis at different body areas (Figure 5). Most 
patients developed skin sclerosis within the first year after RP onset. The probability of having 
a mRSS≥2 in at least one area of the upper extremities within the first year was significantly 
higher than for the lower extremities (68.7%, 95%CI 63.8-73.6 vs. 25.0%, 95%CI 20.6-30.2). 
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Table 2. Comparison of disease characteristics at the baseline visit between patients included 
in this analysis (visit within 1 year after onset of RP) and those excluded (no visit within 1 year 
after onset of RP). 
*data on anti-RNAP-III autoantibodies only available for 317 (45.6%) of the included and 4187 
(45.3%) of the excluded patients. 
 
Patient characteristics at baseline visit Included Excluded P-Value 
Number of patients 695 9196  
Age at onset of RP, years; mean (SD) 51.7 (14.2) 42.4 (14.8) <0.001 
Male, %  26.6 13.3 <0.001 
Laboratory parameters per patient    
ANA, % 96.1 96.4 0.67 
ACA, % 16.7 34.7 <0.001 
Anti-Scl-70, % 42.0 33.2 <0.001 
Anti-RNAP-III*, % 9.5 2.9 <0.001 
Disease characteristics per patient    
Age at onset of first non-RP, years; mean (SD) 50.9 (14.4) 46.3 (14.1) <0.001 
Digital ulcers, % 28.4 34.2 0.002 
Puffy fingers, % 52.7 37.3 <0.001 
mRSS; median (IQR) 10.0 (4.0-19.0) 6 (3.0-12.0) <0.001 
mRSS; mean (SD) 12.7 (10.5) 8.7 (7.7) <0.001 
Diffuse cutaneous involvement, % 20.6 9.0 <0.001 
 
 
As expected, the highest incidence rate of skin sclerosis in the first year was observed at the 
fingers (105.7/100 patient years, 95%CI 92.9-120.1). At the more proximal areas of the upper 
extremities, the incidence in the first year was lower (Figure 5a). The incidence rate of puffy 
fingers in the first year tended to be lower than that of finger skin sclerosis (90.4/100 patient 
years, 95%CI 78.7-103.9), although this difference was not statistically significant. Similarly, the 
more distal areas of the lower extremities were more often affected than the more proximal 
areas (Figure 5b).  
In the central body areas (Figure 5c), the rate of skin sclerosis at the face was similar to that of 
the forearms (42.1/100 patient years, 95%CI 34.4-51.5). The chest and abdomen had rates 
similar to the thighs (17.7/100 patient years, 95%CI 13.0-24.1 and 12.8/100 patient years, 
95%CI 8.9-18.4, respectively). 
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Figure 5. Kaplan-Meier curves with 95%CI of patients developing skin sclerosis defined as ≥2 
points at the area of mRSS scoring, separated for the upper extremities (a), the lower 
extremities (b), and the central body areas (c).  





All patients who developed moderate to severe skin sclerosis (defined as a mRSS≥2 at any body 
area) did so within 6.5 years after RP onset. The probability to develop skin sclerosis within this 
period was 87.7% (95%CI 80.5-92.1) in the upper extremities, and 41.6% (95%CI 33.6-50.8) in 
the lower extremities, 23.4% (95%CI 16.5-32.7) at the chest and 22.0% (95%CI 14.8-32.1) at the 
abdomen.  
When applying a less stringent definition of skin sclerosis, namely a cut off of ≥1 mRSS point at 
any body area, the probability of developing skin sclerosis was 94.7% (95%CI 88.5-98.2); as in 
the case of the more stringent definition for skin sclerosis, all patients developed this within 6.5 
years after RP onset. Thus, about 5.0% of patients had SSc sine scleroderma. 
We also analysed the time of mRSS peaking in patients with skin involvement who had multiple 
visits with a documented mRSS (n=381). The median peak mRSS was 15 points (IQR 7-24; mean 
mRSS 16.7, SD 10.5) and was reached as early as 1.0 year after RP onset (IQR 0.6-2.4; mean 1.9 
years, SD 2.2; Figure 6a; Supplementary Figure 1a). Patients with limited cutaneous involvement 
reached the mRSS peak of 9.5 points (IQR 6-14; mean mRSS 10.4, SD 6.1) after a median of 0.9 
years (IQR 0.6-2.2; mean 2.0, SD 2.5; Figure 6b; Supplementary Figure 1b). For patients with 
diffuse cutaneous involvement, the peak mRSS was 23 points (IQR 16-29.5; mean mRSS 22.8, 
SD 9.6) and was reached after a median of 1.0 year (IQR 0.6-2.5; mean 1.9 years, SD 2.0; Figure 
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6b; Supplementary Figure 1b). Thus, there was no difference in the median time to reach the 
mRSS peak between patients with diffuse and patients with limited cutaneous SSc (p=0.36). We 
also assessed other potential risk factors for the time to mRSS peaking in a multivariable 
analysis only including the first year after RP onset as half of the patients reached their maximal 
mRSS as fast as within this first year. In this analysis, neither patients’ age and sex nor the 
presence of autoantibodies in the patients’ sera was associated with the time to development 
of the maximal mRSS within the first year after RP onset (Supplementary Table 1). 
 
Figure 6. Time to peak mRSS. The histogram plots the percentage of patients as a function of 
the time to reach their maximal mRSS from RP onset; for all patients (a) and divided into 
patients with limited cutaneous involvement and diffuse cutaneous involvement (b).  
The median peak mRSS was 15 points (IQR 7-24) overall, 9.5 points (IQR 6-14) in patients with 
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Skin sclerosis by mRSS severity 
Figure 7a shows the probabilities to develop a total mRSS above 5, 10, 20, 30 or 40 points. Only 
1.2% of patients developed a total mRSS>40 points in the first year. In contrast, the probability 
of having ≤5 mRSS points was 24.1% (95%CI 20.7-27.6) in the first year. 
 
 
Figure 7. Kaplan-Meier curves with 95%CI of patients developing a mRSS >5 points, >10 points, 
>20 points, >30 points and >40 points after the onset of RP (a). Developing a total mRSS >20 
points was further stratified by sex (b), by the median age at the onset of RP (c), and by their 
autoantibody status (d).  
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Men had an almost twofold higher rate than women to develop a mRSS>20 points (rate ratio 
1.8, 95%CI 1.3-2.4) in the first year (Figure 7b). Moreover, age at disease onset was found to be 
a predictor for severe skin involvement (mRSS>20 points) early during the disease course. The 
probability to develop a mRSS>20 points within one year was higher in older patients than in 
younger subjects when dichotomised at the median age (52.7 years, Figure 7c). However, 
within the following 5 years the probabilities of both age groups to develop severe skin 
involvement converged to approximately 42%.  
The analysis of the development of skin sclerosis by the presence of serum autoantibodies in 
the patients’ sera revealed that all patients harbouring anti-RNAP-III autoantibodies and 
develop a total mRSS>20 points did so within 3 years after onset of RP (Figure 7d); the 3-year 
probability was 76.4% (95%CI 57.7-91.1). Patients with anti-Scl-70 autoantibodies also had a 
significantly higher probability of acquiring a mRSS>20 points in the first three years, than 
patients with ACA (44.8%, 95%CI 38.2-52.0 vs. 2.5%, 95%CI 0.6-9.7, respectively). 
 
Diffuse cutaneous involvement 
The probability to develop diffuse cutaneous involvement, defined as a mRSS≥2 at any area of 
the proximal extremities or trunk within the first year was 24.8% (95%CI 20.2-30.3) increasing 
to 35.7% (95%CI 29.9-42.3) during the subsequent two years (Figure 8a). Only a minority of 
patients developed a diffuse cutaneous involvement beyond three years after RP onset. 
The rate of developing diffuse skin involvement in the first year in men was more than twice 
that in women (rate ratio 2.4, 95%CI 1.5-3.96; Figure 8b). There was however no evidence for 
differences in the probability of developing diffuse skin involvement between younger and 
older age groups (Figure 8c).  
With respect to autoantibody status, the rates of developing diffuse cutaneous involvement in 
the first three years were highest in patients with anti-RNAP-III autoantibodies (70.6/100 
patient years, 95%CI 42.7-93.2), followed by those with anti-Scl-70 autoantibodies (43.2/100 
patient years, 95%CI 33.1-54.9), and lowest in patients with ACA (2.3/100 patient years, 95%CI 
0.3-15.1; Figure 8d).  
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Figure 8. Kaplan-Meier curves with 95%CI of the first reported diffuse cutaneous involvement 
after the onset of RP in all patients in this analysis (a), stratified by sex (b), by the median age 
at the onset of RP (c), and by their autoantibody status (d). 





In the multivariable analysis of potential risk factors for the development of diffuse cutaneous 
involvement, defined as signs and symptoms present within the first year after RP onset, the 
presence of anti-RNAP-III and anti-Scl-70 autoantibodies conferred an elevated risk (HR 16.9, 
95%CI 3.7-77.4 and 10.7, 95%CI 2.5-44.9) compared with ACA. Furthermore, male sex was also 
confirmed as a risk factor for diffuse cutaneous involvement (HR 2.7, 95%CI 1.6-4.7, 
supplementary). However, neither patient’s age at RP onset nor the presence of DU or puffy 
fingers were associated with the development of diffuse cutaneous involvement. 
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Digital ulcers 
There was a steep increase of DU development in the first year (Figure 9a), with a probability 
of 33.7% (95%CI 30.0-37.8). Unlike skin sclerosis, the probability of patients to develop DU 
increased continuously over the 10-year observational period to a maximum of 70.2% (95%CI 
60.4-79.5) after the initial steep increase in the first year. The median time to DU development 




Figure 9. Kaplan-Meier curves with 95%CI of the observed first DU after the onset of RP (a), 
stratified by sex (b), by the median age at the onset of RP (c), and by their autoantibody status 
(d).  
Hash marks illustrate censored observations. 
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Men had a significantly higher incidence rate of DU within the first year than women (66.5/100 
patient years, 95%CI 53.0-83.6 vs. 42.0 patient years, 95%CI 35.2-50.1). After 6 years however, 
the probabilities to develop DU converged to approximately 60% in both sexes (Figure 9b). 
Younger patients tended to be affected by DU earlier and more frequently, than older subjects 
(Figure 9c). In contrast to skin sclerosis, patients with anti-RNAP-III had a lower probability to 
develop DU than those with anti-Scl-70 autoantibodies (Figure 9d). Of note, there was no 
difference in the probability between patients with anti-RNAP-III autoantibodies and those with 
ACA. Only the presence of anti-Scl-70 autoantibodies was associated with DU development (HR 
1.8, 95%CI 1.2-2.6) in multivariable analysis, but not the presence of the other autoantibodies, 




This study has analysed prospectively the incidence of SSc skin manifestations in patients who 
present as early as one year after the onset of RP. An important finding is that most patients 
acquire the maximal gain of skin sclerosis within 1 year after RP onset and that diffuse 
cutaneous involvement emerges newly in only a minority of patients after five years of disease 
onset. This study, in which we also map the evolution of skin sclerosis at different body areas, 
underlines, that the fibrotic process is most fulminant initially in all body areas, and less active 
at later stages. The study by Steen and Medsger also highlighted that a mRSS above 40 points 
mainly occurred in the first three years in patients with diffuse cutaneous SSc, but was not able 
to detail the evolution of skin sclerosis during the first three year period and to investigate the 
disease evolution in patients with a mRSS below 40 points [Steen et al., 2000]. 
Our study confirmed that the presence of some autoantibodies is associated with the severity 
of skin sclerosis, as demonstrated in several cross‐sectional studies [Kuwana et al., 1993; Walker 
et al., 2007; Nikpour et al., 2011]. Although two small cross‐sectional studies suggested an 
association between anti‐RNAP‐III autoantibodies and diffuse cutaneous involvement or a 
higher mRSS [Kuwana et al., 1993; Nikpour et al., 2011]. None of these studies compared several 
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autoantibodies simultaneously and none of these studies highlighted the effect of anti‐RNAP‐III 
positivity on the incidence and mRSS kinetics during the early disease course. 
It is still a matter of debate as to whether patients with late‐age onset SSc are more likely to 
have limited or diffuse cutaneous SSc than early‐age onset SSc patients [Derk et al., 2006; Hügle 
et al., 2011; Manno et al., 2011; Alba et al., 2014]. Some investigators found no differences in 
the severity of skin involvement between age‐of‐onset groups [Weng et al., 2010; Hügle et al., 
2011]. In line with a previously published cross‐sectional analysis of our cohort, younger age at 
SSc onset was not associated with a higher mRSS in this longitudinal analysis [Walker et al., 
2007]. 
The short median time to mRSS peaking and the fact that the mRSS gain is highest in the first 
year of disease regardless of the magnitude of the maximal mRSS suggests that SSc kinetics 
peak within the first year in the skin despite inter‐individual differences in the final severity of 
skin sclerosis. Interestingly, the risk factors governing the extent and severity of skin 
involvement (e.g. male sex and autoantibody status being associated with the development of 
diffuse disease), were not found to influence the disease kinetics (e.g. the time to mRSS 
peaking).  
In contrast to the rapid initial evolution of skin sclerosis, the probability to develop DU increased 
more continuously over time. In our study, only the presence of anti‐Scl‐70, and not that of anti‐
RNAP‐III autoantibodies, was associated with an increased incidence of DU, compared to the 
presence of ACA. These findings are in line with several previous studies that suggest a higher 
prevalence of DU in patients with anti‐Scl‐70 autoantibodies compared with patients without 
these autoantibodies [Walker et al., 2007; Hanke et al., 2009]. A small retrospective cohort also 
suggested that patients with anti‐RNAP‐III autoantibodies had less peripheral vascular disease 
than patients with anti‐Scl‐70 autoantibodies, and similar rates to patients with ACA [Vanthuyne 
et al., 2012].  
Most studies agree in the observation that DU are less prevalent in late‐age than young‐age 
onset patients [Walker et al., 2007; Sunderkötter et al., 2009; Hügle et al., 2011; Khimdas et al., 
2011; Manno et al., 2011; Alba et al., 2014]. The univariable analysis of our prospective study 
also highlights a higher DU incidence in patients who are young at disease onset, but 
interestingly this association was lost after controlling for sex and autoantibody status.  
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The strengths of our investigation are the large sample size and the longitudinal multinational 
nature of our cohort. The mRSS score has been validated as a reliable outcome measure and 
demonstrated large effect sizes and sensitivity to change [Clements et al., 1995; Kaldas et al., 
2009]. A somewhat smaller effect size must be taken into account when interpreting skin scores 
of isolated body sites and the mRSS inter-observer variability must be accounted for when 
interpreting cohort data. We also only analysed patients who had been recruited into EUSTAR 
within the first year after RP onset, thereby simulating an inception cohort. This selection and 
the fact that we only recruited patients who fulfilled the ACR classification criteria for SSc is 
however also a limitation of this study, as evidenced by the high prevalence of risk factors 
generally attributed to an adverse outcome (male sex and anti-Scl-70 positivity) in the patients 
included, as compared to those excluded [Perera et al., 2007; Walker et al., 2007; Elhai et al., 
2016]. As a consequence, the patients included had a comparatively higher median mRSS and 
more often diffuse cutaneous involvement at the baseline visit. Therefore, the results of our 
study must not be generalized to patients who present with SSc later than one year after RP 
onset. It should be also noted that the temporal evolution of skin manifestations might be 
underestimated, as some patients already had skin sclerosis at baseline. By including in this 
study only patients with a baseline visit within one year after RP onset, we tried to keep this 
effect low. In future studies, it may be interesting to follow patients who only meet the 
ACR/EULAR and not the ACR classification criteria for SSc and to study drug effects.  
Our study nevertheless critically contributes to the management of those SSc patients who 
present early after RP onset. By mapping the temporal evolution of skin sclerosis and DU and 
identifying risk factors early during the disease course, our findings will enable physicians to 
more accurately counsel SSc patients presenting early. The long-term prospective data on the 
large number of EUSTAR patients presented here will facilitate the design of clinical trials aiming 
to prevent disease evolution as well as those evaluating new diagnostic tests and therapeutic 
strategies.  
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SUPPLEMENTARY MATERIAL 
Supplementary Figure 1. Kaplan-Meier curves with 95%CI of the time to reach the maximal 
mRSS after the onset of RP in all patients in this analysis (a) and divided into patients with 
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Supplementary Table 1. Cox multivariable regression analysis of factors associated with the time to reach the mRSS peak, to develop diffuse 















HR 95%CI HR 95%CI HR 95%CI 
Sex       
Female 1  1  1  
Male 1.26 0.85-1.86 2.72 1.57-4.73 1.23 0.90-1.68 
Age at onset of RP (years) 1.01 0.99-1.02 1.01 0.99-1.03 0.99 0.98-1.00 
Autoantibody status       
ACA 1  1  1  
Anti-Scl-70 1.02 0.67-1.57 10.67 2.54-44.85 1.75 1.20-2.56 
Anti-RNAP-III 1.07 0.53-2.13 16.93 3.70-77.40 0.58 0.26-1.32 
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ARTICLE 2: INCIDENCES AND RISK FACTORS OF ORGAN MANIFESTATIONS IN THE EARLY COURSE OF 
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ABSTRACT 
Objective  
SSc is a rare and clinically heterogeneous autoimmune disorder characterised by fibrosis and 
microvascular obliteration of the skin and internal organs. Organ involvement mostly manifests 
after a variable period of the onset of RP. We aimed to map the incidence and predictors of 
pulmonary, cardiac, GI and renal involvement in the early course of SSc.   
Methods  
In the EUSTAR cohort, patients with early SSc were identified as those who had a visit within 
the first year after RP onset. Incident SSc organ manifestations and their risk factors were 
assessed using Kaplan-Meier methods and Cox regression analysis. 
Results  
Of the 695 SSc patients who had a baseline visit within 1 year after RP onset, the incident non-
RP manifestations (in order of frequency) were: skin sclerosis (75%) GI symptoms (71%), 
impaired diffusing capacity for monoxide<80% predicted (65%), DU (34%), cardiac involvement 
(32%), FVC<80% predicted (31%), increased PAPsys>40mmHg (14%), and renal crisis (3%). In 
the heart, incidence rates were highest for diastolic dysfunction, followed by conduction blocks 
and pericardial effusion. 
While the main baseline risk factor for a short timespan to develop FVC impairment was diffuse 
skin involvement, for PAPsys>40mmHg it was higher patient age. The main risk factors for 
incident cardiac manifestations were anti-Scl-70 autoantibody positivity and older age. Male 
sex, anti-RNAP-III positivity, and older age were risk factors associated with incident renal crisis. 
Conclusion  
In SSc patients presenting early after RP onset, approximately half of all incident organ 
manifestations occur within 2 years and have a simultaneous rather than a sequential onset. 
These findings have implications for the design of new diagnostic and therapeutic strategies 
aimed to ‘widen' the still very narrow ‘window of opportunity'. They may also enable physicians 
to counsel and manage patients presenting early in the course of SSc more accurately.  
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INTRODUCTION 
SSc is a rare and clinically heterogeneous autoimmune disorder. Prevalence estimates vary 
around 20 per 100’000 [Mayes, 2003]. The connective tissue and small vessels are mostly 
affected which leads to the characteristic fibrosis and vascular obliteration of the skin and 
internal organs, particularly of the heart, lungs, kidneys and digestive tract [Rodnan et al., 1979; 
Gabrielli et al., 2009]. In the vast majority of individuals, SSc starts with the onset of RP. Skin 
sclerosis and internal organ involvement manifest mostly either with a variable temporal 
interval after RP onset or simultaneously with RP. 
Numerous cross-sectional studies have already assessed the prevalence of internal organ 
manifestations and calculated risk factors in patients with established SSc [Walker et al., 2007; 
Allanore et al., 2010; Hügle et al., 2011; Manno et al., 2011; Hasegawa et al., 2013; Alba et al., 
2014]. These studies have demonstrated that the presence of specific autoantibodies in the 
patient’s serum, the patient’s sex, and age at SSc onset as well as the extent of skin involvement 
are associated with the prevalence and severity of internal organ involvement [Walker et al., 
2007; Allanore et al., 2010; Assassi et al., 2010; Hügle et al., 2011; Manno et al., 2011; 
Hasegawa et al., 2013; Alba et al., 2014; Avouac et al., 2016; Elhai et al., 2016].  
As internal organ involvement constitutes an important cause of morbidity and mortality, exact 
data about the incidence and temporal evolution of their manifestation after RP onset are 
essential for physicians, who need to counsel patients and risk stratify them early after SSc 
diagnosis; and for investigators, who design and perform a clinical trial aimed at altering the 
natural course of SSc [Kahan et al., 2006; Steen et al., 2007; Omair et al., 2012]. However, only 
few studies have prospectively assessed the evolution of SSc-related organ manifestations after 
the onset of RP. Given the paucity of reliable data, our aim was to map the incidence of internal 
organ manifestations early during the course of disease. By using real-life data from the large 
and multinational EUSTAR cohort [Walker et al., 2007; Meier et al., 2012], we assessed the 
acquisition of pulmonary, cardiac, gastrointestinal or renal involvement in patients who 
developed SSc no later than 1 year after RP onset. 
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PATIENTS AND METHODS  
Study population and design 
The structure of the multicentre and international, prospective, longitudinal EUSTAR database 
has been described previously [Walker et al., 2007; Meier et al., 2012]. Ethics approval 
according to the Declaration of Helsinki has been obtained from all respective contributing 
centers’ local ethics committees and ethics committee approval for the EUSTAR study was 
obtained from the Ethik Kommission Beider Basel (now Ethikkommission Nordwest- und 
Zentralschweiz). Each participating centre obtained local ethics committee approval and 
written informed consent was required to be signed by each patient. Demographic and disease 
characteristics were collected between the time of the database implementation in 2004 and 
February 2014. Data were considered for analysis on the condition that patients were older 
than 18 years at the time of the visit, and fulfilled the 1980 American College of Rheumatology 
(ACR) classification for SSc [Masi et al., 1980]. This dataset is hereafter called the ‘entire EUSTAR 
cohort’. In a second filtering step, the study population was further restricted to patients who 
had a baseline visit within the first year after RP onset, in order to ensure that patients were 




In the entire EUSTAR cohort, the time between RP onset and the onset of the first non-RP 
manifestation of SSc was evaluated. In the restricted study population, the time between RP 
onset and the onset of various organ manifestations was assessed i.e. skin involvement (defined 
as a mRSS ≥2 points in at least 1 body area); GI symptoms (defined as the patient reporting 
either dysphagia, reflux, early satiety, vomiting, diarrhoea, bloating or constipation); a PAPsys 
>40 mmHg as a proxy for suspected pulmonary hypertension; FVC <80% of predicted as a proxy 
for a pulmonary restrictive defect; DU; cardiac involvement (defined as either the presence of 
diastolic dysfunction, conduction blocks, LVEF <50%, or a pericardial effusion); and lastly, renal 
crisis and erectile dysfunction (defined as a score <22 points in the IIEF-5 questionnaire) [Rosen 
et al., 1997]. Table 3 summarises the EUSTAR definitions of the study outcomes assessed. 
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Table 3. Definitions of study outcomes 
Study outcome Description 
Skin involvement A modified Rodnan skin score of 2 or more points in at 
least 1 body area. 
Gastrointestinal symptoms Any of dysphagia, reflux, early satiety, vomiting, 
diarrhoea, bloating and/or constipation as reported by 
the patient. 
Elevated systolic pulmonary 
artery pressure 
A systolic pulmonary artery pressure as estimated by 
echocardiography of more than 40 mmHg as a proxy for 
suspected pulmonary hypertension. 
Impaired forced vital capacity A forced vital capacity of less than 80% of predicted as a 
proxy for a pulmonary restrictive defect. 
Digital ulcers Current ulcers distal to or at the proximal interphalangeal 
joint not thought to be due to trauma. 
Cardiac involvement Any of diastolic dysfunction, conduction blocks, impaired 
left ventricular ejection fraction and/or pericardial 
effusion. 
Diastolic dysfunction As estimated by echocardiography. 
Conduction blocks Atrioventricular block, bundle branch blocks as assessed 
by electrocardiography. 
Impaired left ventricular 
ejection fraction 
A left ventricular ejection fraction less than 50% as 
estimated by echocardiography. 
Pericardial effusion A pericardial effusion of 5mm or more as estimated by 
echocardiography. 
Renal crisis Scleroderma renal crisis as per scleroderma expert 
judgement. 
Erectile dysfunction A score of less than 22 points in the International Index 




Frequencies and percentages as well as medians and IQR and means and SD were reported for 
categorical and continuous variables, respectively. Kaplan-Meier analyses were carried out to 
assess the cumulative probabilities of developing disease features as a function of time after 
RP onset for cases with available information. The date of the visit at which organ 
manifestations were first observed was used as the end time, i.e. the incidence. As the first visit 
was required to be within the first year after RP onset, manifestations that were already present 
at the first visit were also regarded as incident. If the manifestation was never observed, the 
date of the last follow-up visit was set as the censor time. Kaplan-Meier estimates were 
DESSCIPHERING SYSTEMIC SCLEROSIS 
- 62 - 
stratified by sex, age (dichotomized at the median age at RP onset), autoantibody status, and 
diffuse or limited skin involvement. Patients were classified as having diffuse or limited skin 
involvement according to their skin involvement with the first year after RP onset. Strata were 
compared with log-rank tests. Furthermore, incidence rates and their 95% CI were calculated. 
Cox proportional hazards regression analysis was used to assess the combined effect of the 
potential risk factors sex, age, autoantibody status and the extent of skin involvement on 
disease manifestations. All data were analysed with Stata 13.1 (Stata Corporation, College 










At the time of censoring, a total of 11,290 patients were followed in the EUSTAR database. Of 
these patients, 9,891 adult patients fulfilled the 1980 ACR classification criteria for SSc, and 
were therefore included in the subsequent analysis of the entire EUSTAR cohort [Masi et al., 
1980]. The study population, consisting of patients with a baseline visit within the first year 
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after RP onset, was composed of 695 subjects (Figure 10) with a median observation time of 
2.1 years (IQR 0.7-4.6; mean 3.1 years, SD 3.0). The median age of the study population was 
52.7 years (IQR 42.3-62.5) at RP onset, 27% were men (Table 4).  
The other patients followed in the entire EUSTAR cohort were on average about 9 years older 
and about 13% of these were male (Table 4). Compared to the study population, a higher 
percentage of the other patients followed in the entire EUSTAR cohort was ACA positive and a 
lower percentage had anti-Scl-70 or anti-RNAP-III autoantibodies (Table 4). 
 
 
Table 4. Comparison of disease characteristics at the baseline visit between patients included 
in this analysis (visit within 1 year after onset of RP, study population) and those excluded (no 
visit within 1 year after onset of RP). 
* Data were only captured by EUSTAR since 2007; # Number of patients with available 
information for each variable. 
 
Patient characteristics at baseline visit n# Included Excluded P-Value 
Number of patients 695 695 9196  
Age at onset of RP, years; mean (SD) 695 51.7 (14.2) 42.4 (14.8) <0.001 
Male, %  695 26.6 13.3 <0.001 
Laboratory parameters per patient     
ANA, % 683 96.1 96.4 0.67 
ACA, % 648 16.7 34.7 <0.001 
Anti-Scl-70, % 659 42.0 33.2 <0.001 
Anti-RNAP-III*, % 317 9.5 2.9 <0.001 
Disease characteristics at baseline     
Age at onset of first non-RP, years; mean (SD) 607  50.9 (14.4) 46.3 (14.1) <0.001 
Digital ulcers, % 684 28.4 34.2 0.002 
Puffy fingers*, % 375 52.7 37.3 <0.001 
mRSS; median (IQR) 643 10.0 (4.0-19.0) 6 (3.0-12.0) <0.001 
Diffuse cutaneous involvement*, % 327 20.6 9.0 <0.001 
FVC*, % of predicted; mean (SD) 294 90.3 (19.3) 93.5 (21.4) 0.01 
DLCO, % of predicted; mean (SD) 500 68.9 (20.8) 68.9 (20.6) 0.99 
PAPsys*, mmHg; mean (SD) 242 30.2 (12.3) 30.6 (13.2) 0.63 
Diastolic dysfunction, % 621 15.0 17.7 0.08 
Conduction blocks, % 629 8.9 10.7 0.15 
Left ventricular ejection fraction*, %; mean (SD) 284 62.8 (6.4) 62.1 (6.7) 0.12 
Pericardial effusion*, % 286 8.4 6.0 0.11 
Oesophageal symptoms, % 692 56.7 66.2 <0.001 
Stomach symptoms, % 686 19.2 24.4 0.003 
Intestinal symptoms, % 688 16.9 24.5 <0.001 
Renal crisis, % 687 2.6 2.0 0.28 
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Figure 11. Kaplan-Meier curves with 95% CI of the manifestation of any first non-RP feature 
after RP onset in all SSc patients in the entire EUSTAR cohort (A) and stratified by sex (B), the 




Evolution of first non-RP manifestation of SSc in the entire EUSTAR cohort 
In the entire EUSTAR cohort around 87% of patients had their first non-RP feature of the disease 
either after RP onset, or simultaneously with RP onset. The median time from RP onset until 
the first non-RP manifestation of SSc was 0.9 years (IQR 0-4.2), with 90% of patients acquiring 
their first non-RP manifestation within 12.0 years (95%CI 89.5-90.8; Figure 11A). Men 
developed the first non-RP manifestation faster than women (Figure 11B), and older patients 
were affected faster than younger patients (Figure 11C). Patients with anti-RNAP-III and anti-
Scl-70 autoantibodies were more likely to develop a non-RP manifestation faster than patients 
with ACA (Figure 11D). A multivariable analysis confirmed the aforementioned risk factors for 
disease onset (data not shown).  
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Figure 12. Kaplan-Meier curves of incident organ involvement in SSc patients of the study 
population after RP onset. 





Evolution of any organ involvement in the study population 
Among the study population, the probability of developing any organ involvement varied 
among the different organ systems (Figure 12). More than 90% of patients in the study 
population developed either a skin involvement, GI symptoms, or a single breath diffusing 
capacity for monoxide (DLCO)<80% of predicted, the majority of patients within the first year. 
The incidence rates of DU, cardiac involvement and FVC<80% of predicted were considerably 
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Figure 13. Kaplan-Meier curves with 95% CI of incident pulmonary restriction (FVC<80% of 
predicted; (A-D)), suspected pulmonary hypertension (PAPsys>40 mmHg; (E-H)),  cardiac 
involvement (I-L) and renal crisis (M-P) after RP onset in SSc patients of the study population; 
stratified by sex (A/E/I/M), the median age at RP onset (B/F/J/N), autoantibody status (C/G/K/O) 
and extent of skin involvement within the first year after RP onset  (D/H/L/P). 
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Pulmonary complications 
There was no evidence that the frequency and the time to develop a FVC<80% of predicted 
were influenced by the patient’s sex and age (Figure 13A and Figure 13B). There were however 
differences according to the serum autoantibody status (Figure 13C) as patients harbouring 
anti-Scl-70 autoantibodies had a significantly higher incidence of FVC<80% of predicted than 
patients with anti-RNAP-III autoantibodies (incidence ratio 3.6, 95%CI 1.2-17.9), and with ACA 
(incidence ratio 4.7, 95%CI 2.3-10.7). Patients with diffuse skin involvement within the first year 
after RP onset also more frequently had a FVC<80% of predicted than patients with limited skin 
involvement (incidence ratio 2.8, 95%CI 1.8-4.3; Figure 13D). In multivariable analysis, diffuse 
skin involvement within the first year after RP onset was the only significant risk factor for 
incident FVC<80% of predicted (Table 5). 
A FVC<50% of predicted (i.e. a severe pulmonary restrictive defect) was diagnosed in 2% (95%CI 
1-5) of patients within the first year and in 12% (95%CI 6-23) during the 10-year follow-up. 
The probability to develop a DLCO<80% of predicted was high (Figure 12). In multivariable 
analysis, anti-Scl-70 positivity as well as a diffuse skin involvement were the main risk factors 
for incident DLCO<80% of predicted (HR 1.60, 95%CI 1.12-2.28; HR 1.52, 95%CI 1.14-2.02, 
respectively).  
In the first 3 years after RP onset, about one third of patients acquired a DLCO<50% of predicted 
(95%CI 27-36), with a progressive increase to 54% of patients (95%CI 44-65) during the 
observational period. Older patients, male patients, patients with anti-Scl-70 autoantibodies, 
or with diffuse skin involvement had a higher incidence of DLCO<50% of predicted (incidence 
ratios: older vs. younger 1.8, 95%CI 1.3-2.5; male vs. female 1.9, 95%CI 1.4-2.6; anti-Scl-70 vs. 
ACA 3.6, 95%CI 2.0-6.49 diffuse vs. limited 2.9, 95%CI 2.0-4.2). However, only older age, the 
presence of anti-Scl-70 autoantibodies and diffuse skin involvement were confirmed risk 
factors for developing a DLCO<50% of predicted in multivariable analysis (HR 1.03 per 1 year 
increase of age, 95%CI 1.01-1.04; HR 2.64, 95%CI 1.23-5.64; HR 2.06, 95%CI 1.19-3.56, 
respectively). 
The time to develop a PAPsys>40 mmHg was not associated with the patient’s sex or the 
patient’s extent of skin involvement (Figure 13E and Figure 13H). Older patients however 
acquired a PAPsys>40 mmHg faster and more frequently than younger patients (Figure 13F). 
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Patients with anti-RNAP-III autoantibodies showed a PAPsys>40 mmHg less frequently than 
patients harbouring ACA or anti-Scl-70 autoantibodies, but there was no statistically significant 
difference (Figure 13G). Patient’s older age was confirmed to be the main risk factor for 
developing PAPsys>40 mmHg (Table 5).  




Table 5. Cox multivariable regression analysis of risk factors for the time to incident FVC<80% of predicted, PAPsys>40 mmHg, any cardiac dysfunction, 
diastolic dysfunction, conduction block, pericardial effusion and renal crisis.  
















HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI 
Sex               
 Male  1  1  1  1  1  1  1  
 Female 1.30 0.75-2.25 0.40 0.17-0.93 0.85 0.52-1.38 1.09 0.54-2.22 2.12 0.85-5.28  0.46 0.19-1.13 0.39 0.15-0.97 
Age at onset of 
RP (in years) 
1.01 0.99-1.03 1.09 1.05-1.13 1.04 1.02-1.06 1.08 1.04-1.11 1.01 0.99-1.04 1.02 0.98-1.06 1.04 1.00-1.08 
Autoantibody status              
 ACA 1  1  1  1  1  -* - -* - 
 Anti-Scl-70 2.37 0.80-7.03 2.04 0.61-6.80 3.90 1.82-8.35 1.78 0.61-5.20 17.59 3.81-81.33 1  1  
 Anti-RNAP-III 0.62 0.13-2.91 0.49 0.05-4.76 2.56 0.91-7.19 2.09 0.55-8.00 6.62 0.88-49.95 0.31 0.04-2.31 5.18 2.03-13.22 
Extent of skin involvement             
 Limited 1  1  1  1  1  1  1  
 Diffuse 3.08 1.43-6.62 0.91 0.33-2.50 0.93 0.52-1.64 1.78 0.72-4.38 0.45 0.21-0.95 2.86 0.65-12.51 2.96 0.68-12.81 
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Cardiac involvement 
There was no evidence that a patient’s sex was associated with the time to cardiac involvement 
(Figure 13L). Older patients, however, had a 2.1-fold higher incidence (95%CI 1.5-3.0; Figure 
13J) and patients with diffuse skin involvement had a 1.9-fold higher incidence (95%CI 1.3-2.7) 
of cardiac involvement than patients with limited skin involvement (Figure 13L). Patients with 
anti-Scl-70 autoantibodies developed cardiac involvement more frequently and more rapidly 
than patients with ACA (incidence ratio 3.7, 95%CI 2.0-7.4; Figure 13K). In multivariable analysis 
older age and the presence of anti-Scl-70 autoantibodies remained risk factors for any cardiac 
involvement (HR 1.04 per 1 year increase of age and 3.90, respectively; Table 5). 
The most common manifestation of cardiac involvement was diastolic dysfunction (Figure 14). 
The incidence of diastolic dysfunction did not differ between sexes and autoantibody status 
(incidence ratios: male vs. female 1.0, 95%CI 0.6-1.6; ACA vs. anti-Scl-70 0.5, 95%CI 0.2-1.1; 
ACA vs. anti-RNAP-III 0.5, 95%CI 0.2-1.8); though the incidence of diastolic dysfunction was 3.5 
times (95%CI 2.1-5.9) higher in older than in younger patients. The frequency and the time to 
develop a diastolic dysfunction were also influenced by the extent of skin involvement with 
diffuse patients having a 2.1-fold higher incidence (95%CI 1.3-3.4). In the multivariable analysis, 
however, only older age remained a risk factor for diastolic dysfunction (HR 1.08 per 1 year 
increase of age; Table 5).  
Conduction blocks were the second most frequent type of heart involvement (Figure 14). The 
incidence did neither vary by patient’s sex, patient’s age, nor the patient's extent of skin 
involvement; but patients with anti-Scl-70 autoantibodies had a considerably higher incidence 
of conduction blocks than patients with ACA (incidence ratio 10.0, 95%CI 2.5-86.2). In 
multivariable analysis, patients with anti-Scl-70 autoantibodies and patients with anti-RNAP-III 
autoantibodies had an increased risk for conduction blocks, although for the latter, this was not 
statistically significant (Table 5).  
Pericardial effusion was one of the less frequent types of heart involvement. This complication 
evolved more frequently and more rapidly in men, compared to women (incidence ratio 2.7, 
95%CI 1.4-5.4) and in patients with diffuse compared to limited skin involvement (incidence 
ratio 5.6, 95%CI 2.3-16.5). There was no evidence for a difference between age strata. It is 
noteworthy, that none of the patients with ACA developed a pericardial effusion, compared to 
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26% (95%CI 17-39) of patients with anti-Scl-70 autoantibodies. In multivariable analysis, neither 
patient’s sex nor the extent of skin involvement were confirmed as significant risk factors (Table 
5). 
During the first 3 years after RP onset, a LVEF<50% was only observed in 5% of patients (95%CI 
3-9; Figure 14). 
 
 
Figure 14. Kaplan-Meier curves of incident cardiac manifestations after RP onset in SSc in the 
study population.  





Gastrointestinal symptoms  
GI symptoms was one of the most common disease features; at baseline 57% of patients 
reported oesophageal symptoms, 19% stomach symptoms and 17% intestinal symptoms. There 
was no evidence for a difference in the cumulative percentages of GI symptoms when 
stratifying by sex, or autoantibody status (p=0.66 and p=0.16, respectively). However, older 
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patients and patients with diffuse skin involvement tended to acquire a GI symptoms earlier 
and more frequently (p=0.02 and p=0.02, respectively). In multivariable analysis, older age was 
a borderline risk factor (HR 1.01 per 1 year increase in age, 95%CI 1.00-1.02) in contrast to 
diffuse skin involvement (diffuse vs. limited: HR 1.35, 95%CI 1.04-1.76); in addition, patients 
with anti-RNAP-III were less likely to develop GI symptoms than patients with ACA or anti-Scl-
70 autoantibodies (HR 0.55, 95%CI 0.34-0.90; HR 0.59, 95%CI 0.39-0.91, respectively). 
 
Urogenital involvement  
Around 3% (95%CI 2-5) of patients developed a renal crisis within 1 year after the onset of RP 
(Figure 12). The majority of patients who developed a renal crisis did so within the first 4 years. 
Men had a 2.5 times (95%CI 1.2-5.2) higher incidence than women (Figure 13M). There was no 
difference between younger and older patients (Figure 13N). The cumulative percentage of 
renal crisis varied markedly between the autoantibody groups (Figure 13O). Patients with anti-
RNAP-III autoantibodies had a 4.6 times (95%CI 1.6-12.4) higher incidence of renal crisis than 
patients harbouring anti-Scl-70 and none of the patients with ACA developed a renal crisis. 
Patients with diffuse skin involvement developed a renal crisis earlier and more frequently than 
patients with a limited skin involvement (Figure 13P). In multivariable analysis male sex, anti-
RNAP-III positivity, and older age conferred independent risk factors for renal crisis (Table 5).  
The IIEF-5 questionnaire was not included in the EUSTAR database at its inauguration. As a 
consequence, data on erectile dysfunction was only available for 17% (n=32) of men in the 
study population. Around 52% (95%CI 36-70) of these patients reported an erectile dysfunction 
(IIEF-5 score<22) during the first 3 years after RP onset progressing to 95% (95%CI 79-100) 
during the subsequent 6 years. In the first 3 years after onset of RP, about 30% (95%CI 18-52) 
of the men had developed a severe erectile dysfunction (IIEF-5 score<8). Owing to the small 
number of men with data on erectile dysfunction, no further stratification was feasible. 
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DISCUSSION 
This longitudinal study uniquely analysed the incidence of organ manifestations in a large 
cohort of SSc patients early after RP onset and details differences in the evolution of organ 
involvement. Whereas other investigators have analysed the risk factors for disease 
manifestation in patients at risk for SSc (“pre-SSc”, “very early SSc”), the present study has 
focused on the analysis of incident organ manifestations in established disease [Minier et al., 
2014; Valentini, 2015]. 
Skin sclerosis, symptoms of GI tract and a reduced pulmonary diffusing capacity were frequent 
complications of early SSc, incident cardiac complications and pulmonary restriction were 
observed more rarely, followed by elevated systolic pressures of the pulmonary artery and 
renal crisis. Our study also highlights a high incidence of diastolic dysfunction, whereas other 
cardiac complications (conduction blocks, pericardial effusion and left ventricular systolic 
dysfunction) were less frequent [Komócsi et al., 2012].  
In every organ system analysed, approximately half of all organ manifestations that occurred 
during the 10 year observation period became evident within the first 2 years after RP onset. 
Thus, the disease onset followed a simultaneous rather than sequential manifestation pattern. 
Regardless of the differences in the observed frequencies, i.e. the height of the cumulative 
incidences, of these manifestations, the steep increase in manifestations during the first two 
years after RP onset were persistently observed across all organs manifestations studied; even 
complications which are regarded as more severe were not restricted to later disease. Another 
important point is that approximatively 75% of the patients develop organ involvement during 
the 5 first years of the disease. This is good news for the patients who reach that point without 
any organ involvement.  
In line with retrospective prevalence estimates, there were differences in the risk factors 
governing the onset of organ complications [Kuwana et al., 1993; Walker et al., 2007; Hachulla 
et al., 2009; Assassi et al., 2010; Nguyen et al., 2011; Nikpour et al., 2011; Nihtyanova et al., 
2014]. These risk factors modified the cumulative incidences of the organ manifestations but 
did not substantially modify the steep increase in manifestation rates during the first 2 years 
after RP onset. This observation, together with the short interval between RP onset and the 
first non-RP manifestation demonstrates rapid initial disease kinetics and suggests a relatively 
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short ‘window of opportunity’ to prevent incident organ damage [Matucci-Cerinic et al., 2013]. 
Other investigations have also suggested that a variety of severe organ complications 
(pulmonary hypertension and lung fibrosis, among others) are not restricted to late disease 
[Steen et al., 2000; Hachulla et al., 2009].  
The large number of SSc patients and the longitudinal and multinational setup of this study are 
strengths of this investigation. Our study also uniquely simulated an inception cohort by 
including only patients into the study population who had a baseline visit within the first year 
after RP onset. At the same time we introduced a selection bias, as evidenced by the high 
prevalence of factors commonly associated with more prevalent and severe organ 
complications (male sex, older age at SSc onset and anti-Scl-70 autoantibodies) [Perera et al., 
2007; Walker et al., 2007; Graf et al., 2012; Nihtyanova et al., 2014; Elhai et al., 2016]. This 
patient selection could account for the previously unreported association of male sex and renal 
crisis identified in this study and underlines that our findings are specific to SSc patients who 
present with SSc early after RP onset and must not be generalized to all individuals who present 
with SSc. However, as also demonstrated in this study, more than half of all patients in the 
entire EUSTAR cohort experienced their first non-RP feature of the disease within one year of 
the onset of RP. It must be also noted, that some SSc patients had documented organ 
manifestations already at their baseline visit, leading to an overestimation of the time to its 
onset. Lastly, our data may be biased by centre specific differences in the assessment of some 
organ manifestations. With regard to diastolic dysfunction for example, different diagnostic 
approaches are available, each differing in sensitivity and specificity and predictive value [Faludi 
et al., 2014]. Also, the in the EUSTAR database the DLCO collected is not corrected for 
haemoglobin. 
Despite these limitations, our data will likely improve the counselling and management of SSc 
patients early after RP onset. Our findings also have implications for the design of new 
diagnostic strategies and therapeutics aimed to ‘widen’ the still very narrow ‘window of 
opportunity’ [Matucci-Cerinic et al., 2013]. 
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5. SMOKING, A MODIFIABLE RISK FACTOR – DOES IT MAKE IT WORSE?  
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ABSTRACT 
Objectives 
Data on the role of tobacco exposure in SSc severity and progression are scarce. We aimed to 
assess the effects of smoking on the evolution of pulmonary and skin manifestations in the 
EUSTAR database. 
Methods  
Adult SSc patients with data on smoking history and a 12-24 months follow-up visit were 
included. Associations of severity and progression of organ involvement with smoking history 
and the CSI were assessed using multivariable regression analyses.  
Results 
3,319 patients were included (age 57 years; 85% female), 66% were never smokers; 23% ex-
smokers and 11% were current smokers. Current smokers had a lower percentage of anti-Scl-
70 autoantibodies than previous or never smokers (31% vs. 40% and 45%, respectively). 
Never smokers had a higher baseline FEV1/FVC ratio than previous and current smokers 
(p<0.001). The FEV1/FVC ratio declined faster in current smokers than in never smokers 
(p=0.05) or ex-smokers (p=0.01).  
The baseline mRSS and the mRSS decline were comparable across smoking groups. Although 
heavy smoking (more than 25 pack years) increased the odds of digital ulcers by almost 50%, 
there was no robust adverse association of smoking with DU development. 
Conclusion  
The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc 
patients; however, robust adverse effects of smoking on the progression of SSc-specific 
pulmonary or cutaneous manifestations were not observed.  
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INTRODUCTION 
SSc is a rare, multisystem autoimmune disorder [Gabrielli et al., 2009]. Hypoxia and oxidative 
stress have been implicated in the pathophysiology of its generalized microangiopathy and 
fibrosis [Gabrielli et al., 2009]. Although smoking does not appear to confer a risk for SSc 
development [Chaudhary et al., 2011], it has vasoconstrictive effects and increases free radical 
exposure, and together with other proinflammatory and immunomodulatory effects may 
exacerbate SSc manifestations [Zhang et al., 2017]. Data on the role of tobacco exposure with 
regards to the severity of SSc organ manifestations and progression are however scarce and at 
times contradictory [Hudson et al., 2011]. A Canadian cohort study of 606 patients for example 
reported an increased frequency of DU in smokers [Hudson et al., 2011], whereas a study of 
172 Australian patients, found no association of smoking history with vascular characteristics 
[Hissaria, Roberts-Thomson, et al., 2011]. 
Larger studies and robust data assessing the possible effect of smoking on SSc presentations 
and importantly SSc progression are lacking. We therefore assessed the association of tobacco 




This study is based on the multinational, longitudinal EUSTAR database [Walker et al., 2007]. 
Each centre obtained local ethical committee approval; each patient provided written informed 
consent. Data collection started in 2004. The smoking module, however, was introduced to the 
database in 2013; hence, smoking data were only collected from that date onwards. Data for 
this study were exported in May 2017. 
Patients were included if they were older than 18 years, fulfilled the 1980 ACR or 2013 
ACR/EULAR criteria for SSc, and if the smoking status was known; additionally, patients were 
required to have a follow-up visit 12-24 months after baseline. Information about the core data 
collected in EUSTAR can be found elsewhere [Walker et al., 2007]. The EUSTAR smoking module 
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collects patient-reported smoking status (never/previous/current smoker), the number of 
pack-years, and the smoking start and cessation dates.  
The influence of smoking behaviour was assessed on several disease parameters: FEV1/FVC 
ratio, FVC, DLCO/sb, PAPsys, mRSS and DU. Further information about outcome measures as 
well as variables describing the study population can be found in Supplementary Table 2.  




Frequencies/percentages or means/SD were calculated; groups were compared using Χ2-
tests/Fisher’s exact tests or t-tests/ANOVA. Multiple linear and logistic regression analyses 
were applied to adjust outcome/exposure associations with a priori defined potential 
confounding factors (age, sex, time since the onset of RP and since the first non-RP 
manifestation, antibody status, and skin involvement). As the SSc specific antibodies might be 
on the causal pathway between smoking and SSc organ involvement we additionally analysed 
the data without adjustment for antibody status, these results can be found in the 
supplementary (Supplementary Table 3, Supplementary Table 4, Supplementary Table 5). 
Three smoking metrics were modelled separately: (Model 1) never/previous/current smoking, 
(Model 2) smoking intensity (pack-years; never smokers = 0 pack-years, light smokers = 0-10 
pack-years, medium smokers = 10-25 pack-years, heavy smokers = >25 pack-years), and (Model 
3) CSI. The CSI is an index incorporating smoking duration, time since cessation and smoking 
intensity into a single variable [Dietrich et al., 2004; Leffondré et al., 2006]. The CSI depends on 
two parameters which are estimated for each outcome separately: the half-life, i.e. the rate at 
which the smoking’s impact decays over time, and the lag-time, i.e. the delay between smoking 
and its impact.  
Never smokers carry a CSI of 0 and higher CSI values indicate more smoking. The CSI values are 
estimated separately for each outcome variable and hence the CSIs including their ranges are 
different for each outcome variable. The results from the CSI regression analyses should be 
interpreted in the following way: The beta values represent the additive increase or decrease 
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in the outcome variable per unit increase in the CSI. The OR values represent the increase in 
odds for the presence of the outcome variable per unit CSI increase. OR values larger than one 
indicate that increased smoking increases the likelihood of occurrence of the outcome. 
Missing data were imputed using multiple imputation with chained equations [Little, 1988]. The 
regression analyses shown in this paper are all based on imputed data; the results based on a 
complete case analysis are represented in Supplementary Table 7. Analyses were performed 




Patient and smoking characteristics 
Of the 12,912 adult SSc patients within EUSTAR, 6179 (48%) patients had no smoking data 
available; in 3414 (26%) patients had no follow-up visit in the required time frame. Therefore, 
3,319 (26%) patients fulfilled the inclusion criteria (Supplementary Figure 2). The included 
patients had clinically similar demographic and disease characteristics than the excluded 
patients (Supplementary Table 6). On average, a follow-up visit was recorded 1.4 years (SD 0.33) 
after baseline. Patients were on average 57 years old and 85% were female. Demographic and 
disease characteristics are shown in Table 6.  
66% of patients were never smokers, 23% ex-smokers and 11% were current smokers; 13% of 
the current smokers (1.5% of patients) stopped smoking during the observation time on 
average 9 months after the baseline visit. The average ex-smokers had smoked 18 pack-years 
(SD 21) during a time of 19 years (SD 12) and ceased smoking 15 years (SD 13) ago. 49% of the 
ex-smokers had ceased smoking before RP onset and 58% had quit before the onset of the first 
non-RP manifestation. The average current smoker had smoked 27 pack-years (SD 30) during a 
time of 30 years (SD 13).  
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Table 6. Baseline demographic and disease characteristics as well as outcome measures by 
smoking status.  
*based on the follow-up visit, not the 12 months projection. **The changes in outcomes are 
given downscaled to “per 12 month”. #Number of patients with available information for each 
variable. 
 







% or  
mean (SD) 
% or  
mean (SD) 
% or  
mean (SD) 
N   2205 752 362  
Age; years 3319 57.5 (14.1) 57.2 (12.1) 52.5 (11.2) <0.001 
Male sex 3319 8 27 29 <0.001 
Disease characteristics       
Time since RP onset; years  3286 14.9 (11.7) 13.4 (11.3) 13.3 (11.8) 0.001 
Time since first non-RP 
manifestation; years 




Sine 3106 7 8 15 
<0.001 Limited 64 62 58 
Diffuse 29 30 27 
mRSS 2949 7.7 (7.4) 7.8 (7.9) 6.9 (7.3) 0.14 
Follow-up mRSS* 2839 7.4 (7.2) 7.2 (7.1) 6.9 (6.9) 0.40 
Change in mRSS** 2684 -0.3 (3.4) -0.6 (4.0) -0.2 (3.3) 0.12 
Oesophageal symptoms 3275 60 66 58 0.010 
Stomach symptoms 3241 23 23 21 0.68 
Intestinal symptoms 3250 27 30 29 0.24 
Dyspnoea; NYHA 
functional class 
I 3114 57 54 63 
0.001 
II 33 34 31 
III 9 10 5 
IV 1 2 1 
Digital ulcers, current 3125 14 14 16 0.7 
Digital ulcers, ever 3125 46 48 45 0.56 
LVEF; % 2448 62.3 (6.1) 61.7 (6.3) 63.0 (5.8) 0.015 
FEV1/FVC ratio 2256 97.5 (13.5) 95.4 (15.2) 92.8 (15.0) <0.001 
Follow-up FEV1/FVC ratio* 1988 97.1 (12.0) 95.4 (14.5) 90.5 (12.7) <0.001 
Change in FEV1/FVC 
ratio** 
1656 -0.3 (10.1) 0.4 (9.4) -1.6 (7.7) 
0.065 
FVC; % of predicted 2720 96.1  (22.0) 96.7 (21.3) 98.3 (19.7) 0.25 
Follow-up FVC*; % of 
predicted 
2435 95.5 (22.8) 96.3 (22.5) 99.3 (18.8) 0.037 
Change in FVC**; % of 
predicted 
2166 -0.6 (8.5) -0.4 (7.7) 0.1 (9.4) 0.45 
DLCO/sb; % of predicted  2583 69.8 (19.6) 66.4 (20.4) 67.1 (17.8) <0.001 
Follow-up DLCO/sb*; % of 
predicted 
2253 67.5 (20.0) 65.6 (20.0) 64.4 (18.1) 0.021 
Change in DLCO/sb**; % 
of predicted 
1977 -2.0 (9.1) -1.7 (9.2) -2.0 (7.8) 0.86 
PAPsys; mmHg 2317 28.8 (16.9) 26.0 (1.0) 24.3 (12.5) <0.001 
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% or  
mean (SD) 
% or  
mean (SD) 
% or  
mean (SD) 
Follow-up PAPsys*; mmHg 2055 29.2 (13.6) 28.5 (14.1) 24.7 (11.6) <0.001 
Change in PAPsys**; 
mmHg 
1706 0.6 (10.5) 1.6 (8.5) 0.2 (8.1) 
0.18 
Laboratory parameters      
ACA positive 2508 47 47 61 
<0.001 Anti-Scl-70 positive 45 40 31 
Anti-RNAP-III positive 3 6 6 
ESR; mm/hr 2795 22.8 (18.4) 18.9 (16.7) 18.0 (14.5) <0.001 
 
 
As patients with ILD might be more likely to cease smoking than patients without ILD there 
might be a higher percentage of ILD patients in the previous smoker group possibly leading to 
worse trajectories in lung function measures. Therefore, in addition to analysing the entire 
study population, we also analysed the progression of lung function measures separately for 
patients with ILD on HRCT and patients without ILD on HRCT. Among all patients, 49% had signs 
of ILD on HRCT. The smoking behaviour patterns were similar in patients with ILD and in patients 
without ILD; 68% of patients in both groups were never smokers, 23% of patients with and 20% 
of patients without ILD were previous smokers, and 9% of patients with and 12% of patients 
without ILD were current smokers (p=0.06). 
 
FEV1/FVC ratio 
Never smokers had a significantly higher baseline FEV1/FVC ratio than previous and current 
smokers (Table 6). These differences in baseline FEV1/FVC ratio were seen in all three smoking 
models (Figure 15; Table 7; Supplementary Table 8). As can be seen in Table 7, patients had a 
2.7 unit lower FEV1/FVC ratio per unit increase in the CSI. Medium and heavy smokers had 
lower baseline FEV1/FVC ratios than never smokers and light smokers (all p<0.001; 
Supplementary Table 8). In univariable analysis, the FEV1/FVC ratio declined similarly across 
smoking groups (p=0.065); in multivariable analysis, the FEV1/FVC ratio however declined 
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faster in current smokers (Figure 15); this result was also observed when stratifying the study 
population into ILD and non-ILD patients (data not shown). 
 
 
Figure 15. Regression analysis comparing outcomes by smoking status adjusted for age, sex, 
time since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s 
phenomenon manifestation, antibody status and extent of skin involvement.  
Panel A shows the multiple adjusted baseline levels of the outcome measures and 
corresponding 95% confidence intervals and panel B shows the multiple adjusted change rates 
in the outcome measures between baseline and the projected 12 months follow-up. Light grey 







There was no significant difference in baseline FVC and in the FVC change between the three 
smoking groups (Table 6). This lack of a robust effect of smoking on the baseline FVC and on 
the FVC change was also observed in all three multivariable models (Figure 15; Table 7; 
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Supplementary Table 8). This lack was also observed when assessing the FVC changes separately 
for ILD and non-ILD patients (data not shown).  
 
 
Table 7. Regression analysis comparing outcomes at baseline and progression of outcomes 
according to the comprehensive smoking index (CSI) adjusted for age, sex, time since the onset 
of Raynaud’s phenomenon, time since the first non-Raynaud’s phenomenon manifestation, 
antibody status and extent of skin involvement. 
The first column illustrates the mean and the range of each outcome’s CSI based on the 
imputed dataset. Higher CSIs indicate more smoking; never smokers carry a CSI of 0.  
The beta values represent the additive increase or decrease in the outcome variable per unit 
increase in the CSI. The OR values represent the increase in odds for the presence of the 
outcome variable per unit CSI increase. OR values larger than one indicate that increased 
smoking increased the likelihood of occurrence of the outcome.  
The follow-up part of the table assesses the projected change per 12 months of the outcomes. 
 
Outcomes  Mean CSI 
(range) 
CSI 
β or OR 95%CI p-value 
Baseline     
FEV1/FVC 0.45 (0-4.09) β= -2.71 -3.46 to -1.97 <0.001 
FVC 0.34 (0-5.12) β= 0.41 -0.39 to 1.22 0.32 
DLCO/sb 0.27 (0-2.94) β= -4.38 -5.89 to -2.88 <0.001 
PAPsys 0.23 (0-2.61) β= -2.08 -3.57 to -0.58 0.006 
mRSS 0.40 (0-7.05) β= 0.20 -0.03 to 0.43 0.088 
DU current  0.35 (0-7.94) OR= 1.19 1.07 to 1.32 0.002 
Follow-up     
FEV1/FVC 0.33 (0-6.69) β= -0.45 -0.93 to 0.02 0.059 
FVC 0.46 (0-6.36) β= 0.32 -0.01 to 0.66 0.059 
DLCO/SB 0.43 (0-4.02) β= 0.37 -0.16 to 0.90 0.17 
PAPsys 0.35 (0-6.19) β= -0.21 -0.76 to 0.34 0.45 
mRSS 0.43 (0-6.36) β= -0.16 -0.29 to -0.02 0.021 




Smokers had lower baseline DLCO/sb levels than never smokers (p<0.001; Table 6); smoking 
was associated with low baseline DLCO/sb in all three models (Figure 15; Table 7; 
Supplementary Table 8). The DLCO/sb declined similarly across all three smoking behaviour 
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groups in univariable (Table 6) and multivariable analysis (Figure 15; Table 7; Supplementary 




The average baseline PAPsys was slightly higher in never smokers than in current or ex-smokers 
(Table 6). These differences stayed apparent but to a lesser extent not only when assessing the 
smoking groups multivariably, but also evaluating smoking intensity and the CSI (Figure 15; 
Table 7; Supplementary Table 8). The PAPsys increased similarly in the groups in univariable 
(Table 6) and multivariable analysis (Figure 15; Table 7; Supplementary Table 8). 
 
Skin involvement 
No association was evident between the severity of skin fibrosis and the smoking history 
regardless of the smoking matrices used (Table 6; Figure 15; Table 7; Supplementary Table 8). 
SSc sine scleroderma, however, was twice as prevalent in current as in ex- or never smokers 
(Table 6). In all smoking models, no clinically significant difference in mRSS evolution was 
observed (Table 6; Figure 15; Table 7; Supplementary Table 8). 
 
DU 
The prevalence of DUs was comparable in the smoking behaviour groups (Table 6). However, 
heavy smokers had a greater likelihood of DUs than never smokers in multivariable analysis 
(OR=1.6, p=0.02; Supplementary Table 8); also, a higher CSI was associated with the presence 
of DUs at baseline (OR=1.2, p=0.002, i.e. for a one unit increase in CSI, the odds of having DUs 
at baseline increases by a factor of 1.19; Table 7). 
In the sub-group of DU-naïve patients at baseline, 14% of never smokers developed new DUs 
in between the two visits, compared to 16% ex-smokers and 8% current smokers (p=0.05). Ex-
smokers had comparable odds than never smokers to develop DU between the two visits 
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(OR=1.1, p=0.7); current smokers developed DUs less often than never smoking patients 
(OR=0.5, p=0.031). The smoking intensity was not associated with incident DU during the 




Our study is by far the largest prospectively investigating the effect of smoking on SSc 
outcomes. Smoking was common in our patients, however less than in Anglo-Saxon cohorts 
and also much lower than the European average of around 28% [Hissaria, Roberts-Thomson, et 
al., 2011; Hudson et al., 2011; World Health Organization, 2017]. 
The EUSTAR cohort replicated the known adverse effect of smoking on bronchial airways in 
terms of a decline in FEV1/FVC and DLCO. Given the absence of discernible adverse effects of 
smoking on PAPsys the effect of smoking on diffusion capacity may reflect emphysema rather 
than precapillary pulmonary vasculopathy. Adverse effects of smoking on pulmonary airway 
obstruction and diffusing capacity were also seen in two cohorts of 137 SSc and 19 smokers 
[Steen et al., 1985; Greenwald et al., 1987]. In line with one of these cohorts [Steen et al., 1985] 
but in contrast to the second study [Greenwald et al., 1987] we found no association between 
lung compliance (FVC) and smoking status. 
Our study also found no robust effect of smoking on DU prevalence and incidence when 
assessing the smoking behaviour itself or assessing the smoking intensity, similar to two smaller 
studies [Alivernini et al., 2009; Khimdas et al., 2011]. We even found a negative association 
between tobacco exposure and incident DU during the follow-up in a sub-group of DU naïve 
patients (OR=0.5). This effect could not be explained by differences in immunosuppressive and 
vasoactive medication (data not shown). However, when we assessed smoking using the CSI 
we did find an association of smoking on DU prevalence similar to another, however quite 
smaller study also using the CSI [Hudson et al., 2011]. This difference could partially arise due 
to a ‘healthy smoker effect’, although this bias is partly been accounted for by the CSI [Becklake 
et al., 1990]. Given these results, it is difficult to draw robust conclusions on the effect of 
smoking on DUs. 
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In our study, smokers had a lower prevalence of anti-Scl-70 autoantibodies than previous and 
never smokers. This imbalance in autoantibody status is also in line with that found in another 
study, in which anti-Scl-70 positive patients were more likely to be never smokers than ever 
smokers [Chaudhary et al., 2011] raising the possibility of a aethiopathological link between 
smoking and anti-Scl-70 positivity. The question, however, is if this imbalance is partly due to a 
link, maybe a causal one, between smoking and autoantibody status or if this imbalance is partly 
explained by a ‘healthy smoker effect’ especially as the prevalence of anti-Scl-70 positivity in 
previous smokers is more comparable to the never smokers than to current smokers. 
Like all registry-based studies the EUSTAR cohort has limitations. We had no means to verify 
the smoking information provided by the patients; however, we were able to demonstrate 
known adverse effects of smoking on airway obstruction suggesting that the information 
provided by the patients was not random and that our study was powered to detect meaningful 
changes in other parameters.  
By requiring the study population to have a follow-up visit there is a possibility that we excluded 
sicker patients, i.e. that we introduced a selection bias for healthier patients. However, at 
baseline the patients that were excluded due to the absence of a follow-up visit within the 
required time frame were not majorly worse off than the included patients (Supplementary 
Table 6) arguing against a major selection bias. 
In summary, our study demonstrates an adverse effect of smoking on pulmonary airways, but 
no effects on SSc-specific pulmonary and cutaneous involvement. These data argue against a 
major role of tobacco associated free radicals, vasoconstrictory and immunomodulatory effects 
in the pathogenesis of SSc vasculopathy and fibrosis. 
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SUPPLEMENTARY MATERIAL  
Supplementary Table 2. Description of variables selected a priori for the analysis. 
 
Demographics 
 Age (years) 
 Sex (female/male) 
Disease characteristics 
 Time since RP onset (years) 
 Time since first non-RP manifestation (years) 
 Modified Rodnan skin score (mRSS; range 0 to 51)  
 Oesophageal symptoms (yes/no; dysphagia, reflux according to patient)  
 Stomach symptoms (yes/no; early satiety, vomiting according to patient)  
 Intestinal symptoms (yes/no; diarrhoea, bloating, constipation according to patient) 
 Dyspnoea (modified NYHA functional class I to IV;  
Class I: No limitation of physical activity. Ordinary physical activity does not cause undue dyspnoea (shortness of breath). 
Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in dyspnoea.  
Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes dyspnoea. 
Class IV: Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. ) 
 Digital ulcers (yes/no; current ulcers distal to or at the proximal interphalangeal joint) 
 Systolic pulmonary artery pressure (PAPsys, mmHg; as estimated by echocardiography) 
 Single breath diffusing capacity for carbon monoxide (DLCO, % of predicted) 
 Forced vital capacity (FVC, % of predicted) 
 Forced expiratory volume in one second; (FEV1, % of predicted) 
 Left ventricular ejection fraction (LVEF, %) 
Laboratory 
 Anticentromere autoantibodies positivity (ACA; yes/no) 
 Anti-topoisomerase autoantibodies positivity (anti-Scl-70; yes/no) 
 Anti-RNA polymerase-III autoantibodies positivity (anti-RNAP-III; yes/no) 
 Erythrocyte sedimentation rate (ESR; mm/hour) 
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Supplementary Table 3. Linear and logistic regression analyses comparing outcomes in previous and current smokers with that of never smokers 
adjusted for age, sex, time since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s phenomenon manifestation, and extent of 
skin involvement but not adjusted for antibody status.  
Results are based on the multiple imputed data. 
The beta values represent the increase or decrease in the outcome variable of previous or current smokers compared to never smokers. The OR 
values represent the increase in odds for the presence of the outcome variable of previous or current smokers compared to never smokers. The 
follow-up part of the table assesses the projected change per 12 months of the outcomes. 
 
Outcomes Previous smokers Current smokers 
β or OR 95%CI p-value β or OR 95%CI p-value 
Baseline       
FEV1/FVC β= -2.82 -4.2 to -1.4 <0.001 β= -5.72 -7.5 to -3.9 <0.001 
FVC (% of predicted) β= 1.72 -0.1 to 3.5 0.063 β= 4.23 1.8 to 6.6 0.001 
DLCO/sb (% of predicted) β= -3.53 -5.3 to -1.8 <0.001 β= -3.63 -6.0 to -1.3 0.003 
PAPsys (mmHg) β= -2.11 -3.6 to -0.6 0.006 β= -2.76 -4.7 to -0.8 0.006 
mRSS β= 0.14 -0.4 to 0.6 0.60 β= -0.42 -1.1 to 0.3 0.23 
DU current OR= 1.02 0.8 to 1.3 0.89 OR= 1.19 0.9 to 1.6 0.31 
Follow-up       
FEV1/FVC β= 0.64 -0.4 to 1.7 0.22 β= -1.18 -2.5 to 0.2 0.085 
FVC (% of predicted) β= 0.11 -0.8 to 1.0 0.80 β= 0.74 -0.4 to 1.9 0.22 
DLCO/sb (% of predicted) β= 0.74 -0.3 to 1.8 0.17 β= 0.25 -1.1 to 1.6 0.73 
PAPsys (mmHg) β= 1.00 -0.1 to 2.1 0.082 β= -0.29 -1.9 to 1.3 0.72 
mRSS β= -0.39 -0.7 to -0.1 0.014 β= -0.14 -0.6 to 0.3 0.51 
DU new btw visits OR= 1.08 0.8 to 1.5 0.66 OR= 0.50 0.3 to 0.9 0.018 
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Supplementary Table 4. Linear and logistic regression analyses comparing outcomes in light, medium or heavy smokers with that of never smokers 
adjusted for age, sex, time since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s phenomenon manifestation, and extent of 
skin involvement but not adjusted for antibody status.  
Results are based on the multiple imputed data. 
The beta values represent the increase or decrease in the outcome variable of light, medium or heavy smokers compared to never smokers. The OR 
values represent the increase in odds for the presence of the outcome variable of light, medium or heavy smokers compared to never smokers. The 
follow-up part of the table assesses the projected change per 12 months of the outcomes. 
 
Outcomes >0 to 10 pack-years >10 to 25 pack-years >25 pack-years 
β or OR 95%CI p-value β or OR 95%CI p-value β or OR 95%CI p-value 
Baseline          
FEV1/FVC β= -1.84 -3.7 to 0.01 0.050 β= -4.41 -6.4 to 2.5 <0.001 β= -6.01 -8.2 to -3.8 <0.001 
FVC (% of predicted)  β= 3.28 1.0 to 5.5 0.004 β= 3.19 0.6 to 5.8 0.016 β= 0.48 -2.2 to 3.1 0.73 
DLCO/sb (% of predicted)  β= -2.22 -4.4 to -0.1 0.043 β= -2.94 -5.4 to -0.5 0.021 β= -6.43 -9.1 to -3.8 <0.001 
PAPsys (mmHg) β= -1.89 -3.7 to -0.04 0.045 β= -3.01 -5.0 to -1.0 0.003 β= -2.20 -4.4 to 0.02 0.052 
mRSS β= -0.18 -0.8 to 0.5 0.59 β= -0.31 1.0 to 0.4 0.41 β= 0.50 -0.3 to 1.3 0.21 
DU current  OR= 0.86 0.6 to 1.2 0.41 OR= 1.07 0.7 to 1.6 0.71 OR= 1.47 1.0 to 2.2 0.045 
Follow-up          
FEV1/FVC  β= 0.01 -1.3 to 1.3 0.99 β= -0.24 -1.6 to 1.1 0.72 β= 0.51 -0.9 to 2.0 0.49 
FVC (% of predicted)  β= 0.44 -0.7 to 1.5 0.43 β= 0.29  -1.0 to 1.6 0.67 β= 0.14 -1.1 to 1.4 0.83 
DLCO/sb (% of predicted) β= 0.64 -0.6 to 1.9 0.32 β= 0.49 -0.8 to 1.8 0.47 β= 0.59 -0.9 to 2.0 0.42 
PAPsys (mmHg) β= 0.54 -0.8 to 1.9 0.44 β= 0.94 -0.7 to 2.5 0.25 β= 0.28 -1.5 to 2.1 0.76 
mRSS β= -0.37 -0.8 to 0.03 0.067 β= -0.08 -0.52 to 0.37 0.74 β= -0.49 -1.0 to -0.02 0.043 
DU new btw visits OR= 0.80 0.5 to 1.3 0.36 OR= 0.96 0.6 to 1.5 0.88 OR= 0.87 0.5 to 1.5 0.62 
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Supplementary Table 5. Regression analysis comparing outcomes according to the comprehensive smoking index (CSI) adjusted for age, sex, time since 
the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s phenomenon manifestation, and extent of skin involvement but not adjusted 
for antibody status.  
Results are based on the multiple imputed data. 
Higher CSIs indicate more smoking; never-smokers carry a CSI of 0. The beta values represent the additive increase or decrease in the outcome 
variable per unit increase in the CSI. The OR values represent the increase in odds for the presence of the outcome variable per unit CSI increase. OR 
values larger than one indicate that increased smoking increased the likelihood of occurrence of the outcome.  
The follow-up part of the table assesses the projected change per 12 months of the outcomes. 
 
Outcomes  CSI 
β or OR 95%CI p-value 
Baseline    
FEV1/FVC β= -3.00 -3.8 to -2.3 <0.001 
FVC β= 1.08 0.3 to 1.9 0.010 
DLCO/sb β= -3.71 -5.2 to -2.2 <0.001 
PAPsys β= -2.26 -3.8 to -0.8 0.003 
mRSS β= 0.19 -0.04 to 0.4 0.11 
DU current OR= 1.16 1.0 to 1.3 0.004 
Follow-up    
FEV1/FVC β= -0.41 -0.9 to 0.1 0.091 
FVC β= 0.28 -0.1 to 0.6 0.099 
DLCO/sb β= 0.33 -0.2 to 0.9 0.22 
PAPsys β= -0.17 -0.7 to 0.4 0.53 
mRSS β= -0.17 -0.3 to -0.04 0.013 
DU new btw visits OR= 0.81 0.7 to 1.0 0.034 
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Supplementary Table 6. Comparison of included and excluded patients.  
 
Baseline characteristics of 
the study population 
Included patients 
(mean [SD] or %) 
Excluded patients 
(mean [SD] or %) 
p-value (comparing 
included and excluded 
patients) 
Excluded due to no 
follow-up visit 12-24 
months after baseline 
(mean [SD] or %) 
p-value (comparing 
included and excluded 
due to lack of follow-
up visit) 
N  3319 9593  3414  
Smoking 
behaviour 
Never 66   69 0.001 
Previous 23   19 
Current 11   12 
Age; years 56.9 (13.5) 55.8 (14.0) <0.001 55.5 <0.001 
Male sex 15 15 0.77 15 0.55 
Disease characteristics       
Time since RP onset; years  14.4 (11.6) 12.0 (11.3) <0.001 11.5 (11.2) <0.001 
Time since first non-RP 
manifestation; years 
11.1 (8.8) 8.5 (9.4) <0.001 8.1 (9.7) <0.001 
Skin 
involvement 
Sine 8 2 <0.001 6 0.007 
Limited 63 64 64 
Diffuse 29 34 30 
mRSS 7.7 8.8 <0.001 8.7 <0.001 
Oesophageal symptoms 61 64 <0.001 64 0.007 
Stomach symptoms 22 23 0.47 21 0.15 




I 57 54 <0.001 54 0.14 
II 33 34 35 
III 9 11 10 
IV 1 1 1 
Digital ulcers, current 14 15 0.40 15 0.41 
Digital ulcers, ever 47 43 0.004 43 0.012 
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LVEF; % 62.2 (6.1) 62.2 (7.0) 0.99 62.3 (6.9) 0.77 
FEV1/FVC ratio 96.5 (14.2) 98.6 (14.7) <0.001 98.0 (14.2) 0.001 
FVC; % of predicted 96.5 (21.6) 93.1 (22.0) <0.001 94.9 (22.5) 0.012 
DLCO/sb; % of predicted  68.7 (19.7) 68.8 (28.2) 0.89 70.1 (20.7) 0.015 
PAPsys; mmHg 27.7 (16.0) 29.9 (15.6) <0.001 28.1 (15.2) 0.31 
Laboratory parameters      
ACA positive 48 49 <0.001 53 0.002 
Anti-Scl-70 positive 43 46 40 
Anti-RNAP-III positive 4 2 3 
ESR; mm/hr 21.4 (17.7) 23.5 (19.9) <0.001 22.2 (19.4) 0.11 
  
DESSCIPHERING SYSTEMIC SCLEROSIS 
- 95 - 
 
 
Supplementary Table 7. Linear and logistic regression analyses in previous and current smokers with that of never smokers adjusted for age, sex, time 
since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s phenomenon manifestation, antibody status and extent of skin 
involvement.  
Results are based on complete cases. 
The beta values represent the increase or decrease in the outcome variable of previous or current smokers compared to never smokers. The OR 
values represent the increase in odds for the presence of the outcome variable of previous or current smokers compared to never smokers. The 
follow-up part of the table assesses the projected change per 12 months of the outcomes. 
 
Outcomes Previous smokers Current smokers 
β or OR 95%CI p-value β or OR 95%CI p-value 
Baseline       
FEV1/FVC  β= -2.11 -3.9 to -0.3 0.021 β= -5.25 -7.7 to -2.7 <0.001 
FVC (% of predicted)  β= 0.43 -1.8 to 2.7 0.70 β= 1.56 -1.5 to 4.6 0.32 
DLCO/sb (% of predicted)  β= -3.75 -6.0 to -1.5 0.001 β= -6.02 -9.1 to -2.9 <0.001 
PAPsys (mmHg) β= -2.38 -4.3 to -0.4 0.018 β= -2.17 -4.8 to 0.5 0.11 
mRSS  β= 0.03 -0.7 to 0.8 0.94 β= -0.55 -1.6 to 0.5 0.31 
DU current OR= 1.06 0.8 to 1.5 0.71 OR= 1.29 0.9 to 1.9 0.21 
Follow-up       
FEV1/FVC  β= 1.02 -0.3 to 2.4 0.14 β= -1.17 -3.0 to 0.7 0.22 
FVC (% of predicted)  β= -0.14 -1.2 to 1.0 0.80 β= 1.14 -0.4 to 2.6 0.14 
DLCO/sb (% of predicted)  β= 0.31 -1.0 to 1.6 0.63 β= 0.42 -1.3 to 2.1 0.63 
PAPsys (mmHg)  β= 0.52 -0.9 to 2.0 0.49 β= -1.19 -3.2 to 0.8 0.24 
mRSS  β= -0.43 -0.8 to -0.03 0.033 β= -0.40 -1.0 to 0.1 0.15 
DU new btw visits  OR= 1.37 0.9 to 2.1 0.15 OR= 0.65 0.3 to 1.3 0.22 
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Supplementary Table 8. Linear and logistic regression analysis comparing outcomes in light, medium or heavy smokers with that of never smokers 
adjusted for age, sex, time since the onset of Raynaud’s phenomenon, time since the first non-Raynaud’s phenomenon manifestation, antibody status 
and extent of skin involvement.  
The results are based on the multiple imputed data. 
The beta values represent the increase or decrease in the outcome variable of light, medium or heavy smokers compared to never smokers. The OR 
values represent the increase in odds for the presence of the outcome variable of light, medium or heavy smokers compared to never smokers. The 
follow-up part of the table assesses the projected change per 12 months of the outcome. 
 
Outcomes >0 to 10 pack-years >10 to 25 pack-years >25 pack-years 
β or OR 95%CI p-value β or OR 95%CI p-value β or OR 95%CI p-value 
Baseline          
FEV1/FVC  β= -1.50 -3.34 to 0.34 0.11 β= -3.65 -5.59 to -1.72 <0.001 β= -5.35 -7.56 to -3.15 <0.001 
FVC (% of predicted) β= 2.5 0.33 to 4.67 0.024 β= 1.39 -1.12 to 3.91 0.28 β= -1.12 -3.70 to 1.47 0.40 
DLCO/sb (% of predicted) β= -2.57 -4.71 to -0.44 0.018 β= -3.82 -6.33 to -1.31 0.003 β= -7.29 -9.92 to -4.65 <0.001 
PAPsys (mmHg) β= -1.84 -3.69 to 0.01 0.051 β= -2.83 -4.85 to -0.81 0.006 β= -1.97 -4.19 to 0.24 0.080 
mRSS β= -0.13 -0.79 to 0.53 0.71 β= -0.22 -0.94 to 0.51 0.55 β= 0.54 -0.24 to 1.32 0.17 
DU current* OR= 0.89 0.63 to 1.26 0.52 OR= 1.16 0.80 to 1.70 0.43 OR= 1.59 1.08 to 2.34 0.019 
Follow-up          
FEV1/FVC β= -0.018 -1.35 to 1.31 0.98 β= -0.36 -1.72 to 1.00 0.60 β= 0.35 -1.12 to 1.81 0.64 
FVC (% of predicted) β= 0.43 -0.67 to 1.52 0.44 β= 0.34 -0.96 to 1.63 0.61 β= 0.26 -1.02 to 1.54 0.69 
DLCO/sb (% of predicted) β= 0.63 -0.65 to 1.92 0.33 β= 0.53 -0.81 to 1.86 0.44 β= 0.68 -0.75 to 2.11 0.35 
PAPsys (mmHg) β= 0.53 -0.83 to 1.88 0.45 β= 0.92 -0.69 to 2.52 0.26 β= 0.27 -1.56 to 2.10 0.77 
mRSS β= -0.34 -0.74 to 0.06 0.09 β= -0.01 -0.05 to 0.43 0.95 β= -0.44 -0.93 to 0.04 0.07 
DU new btw visits* OR= 0.80 0.49 to 1.30 0.37 OR= 0.99 0.58 to 1.69 0.97 OR= 0.90 0.52 to 1.58 0.72 
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6. PHYSICAL FUNCTION IN SYSTEMIC SCLEROSIS - THE PATIENT PERSPECTIVE  
ARTICLE 4: FUNCTIONAL DISABILITY AND ITS PREDICTORS IN SYSTEMIC SCLEROSIS: A STUDY FROM 
THE DESSCIPHER PROJECT WITHIN THE EUSTAR GROUP 
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ABSTRACT 
Objectives  
The multisystem manifestations of SSc can greatly impact patients’ quality of life. The aim of 
this study was to identify factors associated with disability in SSc  
Methods 
SSc patients from the prospective DeSScipher cohort who had completed the SHAQ, a disability 
score that combines the health assessment questionnaire and five VAS, were included in this 
analysis. The effect of factors possibly associated with disability was analysed with multiple 
linear regressions.  
Results 
The mean SHAQ and HAQ scores of the 944 patients included were 0.87 (SD 0.66) and 0.92 (SD 
0.78). 59% of the patients were in the “mild to moderate difficulty” SHAQ category (0≤SHAQ<1), 
34% in the “moderate to severe disability” category (1≤SHAQ<2) and 7% in the “severe to very 
severe disability” category (2≤SHAQ≤3). The means of the VAS scores were in order of 
magnitude: overall disease severity (37mm), Raynaud’s phenomenon (31mm), pulmonary 
symptoms (24mm), gastrointestinal symptoms (20mm) and digital ulcers (19mm). 
In multiple regression, the main factors associated with high SHAQ scores were the presence 
of dyspnoea (modified NYHA-class IV (regression coefficient B=0.62), modified NYHA III 
(B=0.53) and modified NYHA II (B=0.21; all vs. modified NYHA-class I), fibromyalgia (B=0.37), 
muscle weakness (B=0.27), DU (B=0.20) and gastrointestinal symptoms (oesophageal 
symptoms, B=0.16; stomach symptoms, B=0.15; intestinal symptoms, B=0.15). 
Conclusions 
SSc patients perceive dyspnoea, pain, DUs, muscle weakness and gastrointestinal symptoms as 
the main factors driving their level of disability, unlike physicians who emphasize objective 
measures of disability.  
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INTRODUCTION 
SSc is a rare, clinically heterogeneous multisystem disorder which greatly affects the patients’ 
physical and psychological functioning and impairs their ability to participate in work and social 
activities. Substantial morbidity results from DU, skeletal muscle weakness, contractures, 
cardiopulmonary and gastrointestinal involvement [Johnson et al., 2006; Hudson et al., 2009; 
Mouthon et al., 2010]. One of the most formidable goals of care is to alleviate symptoms and 
disability and to improve the health-related QoL and functional ability [Kwakkenbos et al., 
2013].  
Whereas physicians tend to emphasize objective measures of disease status, patients may 
perceive other aspects of their disease as more disabling or burdensome [Suarez-Almazor et 
al., 2007]. The evaluation of SSc severity and its impact on activities of daily living requires 
several measures due to multiple organ involvement; single organ outcome measures only 
provide limited information [Steen and Medsger, 1997].  
The HAQ is one of the most commonly used measures of disability in musculoskeletal disorders 
and is also used in SSc as a simple, inexpensive and practical way to reflect the patient 
perspective [Bruce et al., 2003a, 2005; Johnson et al., 2005; Pope, 2011]. The HAQ is a self-
reported questionnaire consisting of twenty questions split across eight domains, addressing 
rising, eating, walking, hygiene, dressing, reach, grip and usual activities [Bruce et al., 2003b]. 
The HAQ was extended to form the SHAQ, a more disease-specific disability scale that 
incorporates the HAQ and five scleroderma related VAS into one score [Steen and Medsger, 
1997]. The five VASs in the SHAQ assess the level of impairment due the complications 
frequently observed in SSc outside the musculoskeletal system, namely RP, DUs, 
gastrointestinal symptoms, respiratory symptoms, as well as the overall severity of the disease 
from the patient’s perspective [Steen and Medsger, 1997]. The SHAQ is a reliable and valid 
measure of functional disability in SSc [Steen and Medsger, 1997; Merkel et al., 2002; Smyth et 
al., 2003; Johnson et al., 2005; Pope, 2011].  
Several studies have assessed the impact of selected SSc-specific symptoms on patients’ life 
[Franck-Larsson et al., 2009; Mouthon et al., 2010; Omair et al., 2012; Hughes et al., 2015; 
Racine et al., 2016], or assessed overall QoL or functional disability and factors associated with 
it [Smyth et al., 2003; Hudson et al., 2009; Strickland et al., 2012]. However, due to the rarity 
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of the disease, most of these studies have a limited sample size and focus on sub-populations, 
for example only patients with DUs or patients with pulmonary hypertension [Chow et al., 2008; 
Strickland et al., 2012; Guillevin et al., 2013; Lumetti et al., 2015]. Recently, one large internet-
based survey assessed patients’ perception on factors impacting on the daily lives, as well as 
health related quality of life [Frantz et al., 2016]. This study however was a purely patient based 
survey with no linkage to clinical data.  
Our aim was therefore to prospectively analyse functional disability in a large cohort of SSc 
patients not selected for a particular organ manifestation, and to identify clinical factors 




Study population and design 
The DeSScipher (“to decipher the optimal management of systemic sclerosis“ [The DeSScipher 
Project, 2013; Frerix et al., 2015]) project is a multinational, longitudinal study embedded in the 
EUSTAR group database [Walker et al., 2007; Meier et al., 2012]. The DeSScipher project 
consists of five observational trials focusing on DU, hand arthritis, interstitial lung disease, 
pulmonary hypertension and severe heart disease. However, DeSScipher patients as such are 
not selected for any specific organ manifestations  as the DeSScipher cohort consists of EUSTAR 
patients being followed at DeSScipher centres during the DeSScipher project regardless of 
organ manifestations and eligibility into any of the DeSScipher observational trials (please see 
the DeSScipher website for more detail [The DeSScipher Project, no date]).  
DeSScipher data were collected prospectively in a multicentre approach. Data collection for the 
DeSScipher project started in March 2013, however the recording of the SHAQ within the 
DeSScipher database only started in October 2014, and was independent of particular organ 
manifestations, SSc treatments or eligibility for a specific DeSScipher observational trial. Data for 
this study were exported in August 2016. Each DeSScipher centre obtained ethical approval by 
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its local ethics committee; written informed consent according to the declaration of Helsinki 
was required from each patient prior to enrolment.  
All patients had to fulfill either the 1980 ACR criteria for SSc, or the 2013 ACR/EULAR criteria 
and were eligible for this analysis if they were above 18 years of age and had at least one SHAQ 
available [Masi et al., 1980; Steen and Medsger, 1997; van den Hoogen et al., 2013]. Patients 
were classified as diffuse or limited SSc depending on the most severe skin involvement at the 
time of the study visit or any prior visit.  
The HAQ built into the SHAQ has a recall period of seven days, ranges from 0 to 3 and is 
categorised into mild to moderate difficulty (score of  0 to <1), moderate to severe disability 
(score of 1 to <2) and severe to very severe disability (score of 2 to 3) [Bruce et al., 2003b, 
2003a]. The VAS scales in the SHAQ assess the interference of the disease with daily activities 
and range from 0 (not limiting activities) to 100 (very severe limitation). In the original version 
of the SHAQ no combined score was built, instead the HAQ and the five VAS were assessed 
separately [Steen and Medsger, 1997]. Georges et al. proposed to average the eight HAQ 
categories and the five VASs (each downscaled to range from 0 to 3) into a composite SHAQ 
score ranging from 0 to 3 [Georges et al., 2005]. For this cross-sectional study, the first SHAQ 
recorded was analysed.  
  
Statistical analysis 
Depending on the categorical or continuous nature of the variables, frequencies and 
percentages or means and SD were calculated. For categorical variables, between group 
comparisons were carried out using Χ2-tests or Fisher’s exact tests; t-tests were used for 
continuous variables. Missing data of covariates were imputed using multiple imputations by 
chained equations [Sterne et al., 2009; Carpenter et al., 2013].  
After defining possible predictors of functional disability a priori (Table 8), predictors were 
identified using univariable and multivariable linear regression analyses. We decided not to 
include the SSc subset of the patients and sclerodactyly in the multivariable model, as these 
variables are strongly related to the mRSS.  
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Table 8. Description of possible predictors selected a priori for the analysis. 
Demographics 
 Age (years) 
Sex (female/male) 
Disease characteristics 
 Time since RP onset (years) 
Time since first non-RP manifestation (years) 
 Modified Rodnan skin score (mRSS; range 0 to 51)  
 Oesophageal symptoms (yes/no; dysphagia, reflux according to patient)  
Stomach symptoms (yes/no; early satiety, vomiting according to patient)  
Intestinal symptoms (yes/no; diarrhoea, bloating, constipation according to patient) 
Any gastrointestinal symptoms (yes/no; any of oesophageal, stomach or intestinal 
symptoms) 
Number of gastrointestinal symptoms (range 0 to 3; oesophageal, stomach and/or 
intestinal symptoms) 
 Dyspnoea (modified NYHA functional class I to IV;  
Class I: No limitation of physical activity. Ordinary physical activity does not cause 
undue dyspnoea (shortness of breath). 
Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in dyspnoea.  
Class III: Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity causes dyspnoea. 
Class IV: Unable to carry out any physical activity without discomfort. Symptoms of 
cardiac insufficiency at rest. ) 
 
 
Puffy fingers (yes/no; current scleredema) 
Digital ulcers (yes/no; current ulcers distal to or at the proximal interphalangeal joint) 
 Telangiectasia (yes/no) 
 Joint synovitis (yes/no; by rheumatologist’s judgement) 
Joint contractures (yes/no; by rheumatologist’s judgement) 
Muscle weakness (yes/no; by rheumatologist’s judgement defined as a paresis 
unexplained by a neuropathy or contracture) 
Muscle atrophy (yes/no; by rheumatologist’s judgement) 
Fibromyalgia (yes/no; by rheumatologist’s judgement) 
 Systolic pulmonary artery pressure (PAPsys, mmHg; as estimated by echocardiography) 
 Single breath diffusing capacity for carbon monoxide (DLCO, % of predicted) 
Forced vital capacity (FVC, % of predicted) 
Lung fibrosis on HRCT (yes/no) 
 Conduction blocks (yes/no; AV-block, bundle branch blocks) 
Diastolic dysfunction (yes/no) 
Pericardial effusion (yes/no)  
Left ventricular ejection fraction (LVEF, %) 
Laboratory 
 Anticentromere autoantibodies positivity (ACA; yes/no) 
Anti-topoisomerase autoantibodies positivity (anti-Scl-70; yes/no) 
Anti-RNA polymerase-III autoantibodies positivity (anti-RNAP-III; yes/no) 
Erythrocyte sedimentation rate (ESR; mm/hour) 
Serum creatinine kinase elevation (CK; yes/no) 
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To compare levels of disability in patients with diffuse SSc and limited SSc we reduced the 
original model to factors that were strong and clinically significant predictors of functional 
disability in the overall patient group or were defined a priori.  
The MCID of the HAQ is stated to be ≥0.22 [Wells et al., 1993]. As the SHAQ is based on the 
HAQ and has the same range, we applied this threshold also to the SHAQ. We treated a 
difference of ≥10mm as the MCID for the VAS components [Wells et al., 1993; Dworkin et al., 
2008; Strand et al., 2011].  





At the time of the data export, 944 (38%) of the 2,488 adult DeSScipher patients had a SHAQ 
score. During the time of the SHAQ collection, 2084 patients had a visit after the introduction 
of the SHAQ, therefore 45% of eligible patients had a SHAQ score available. The demographic 
and disease characteristics of this study population are listed in Table 9.  
Of the 944 patients, 115 (12.2%) fulfilled only the 2013 ACR/EULAR criteria but not the 1980 
ACR classification criteria for SSc. Patients included in the study were of similar age and sex 
distribution as the patients excluded for the lack of a SHAQ. Additionally, both groups had 
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Table 9. Demographic and disease characteristics of the study population at the time of SHAQ 
assessment (n=944).  
Characteristics of the study population (N=944)       % or mean (SD) 
Age; years 56.8 (13.0) 
Male sex 15.0 
Disease characteristics   
Time since RP onset; years  14.8 (11.9) 
Time since first non-RP manifestation; years 11.5 (9.1) 






Oesophageal symptoms 62.7 
Stomach symptoms 26.6 








Sclerodactyly  72.5 
Puffy fingers 42.8 
Digital ulcers 13.2 
Telangiectasia 74.9 
Joint synovitis 11.4 
Joint contractures 50.5 
Tendon friction rubs 4.6 
Muscle weakness 16.7 
Muscle atrophy 6.7 
Fibromyalgia 4.0 
Conduction blocks 17.7 
Diastolic dysfunction 45.2 
Pericardial effusion 1.8 
LVEF; % 62.2 (5.4) 
LVEF <50% 1.3 
PAPsys; mmHg 29.8 (12.1) 
PAPsys >40mmHg 10.6 
DLCO; % of predicted  63.3 (19.3) 
FVC; % of predicted 94.8 (21.5) 
FVC <80% of predicted 23.3 
Lung fibrosis on HRCT 59.8 
Laboratory parameters  
ANA positive 98.2 
ACA positive 38.7 
Anti-Scl-70 positive 48.4 
Anti-RNAP-III positive 6.2 
ESR; mm/hr 19.8 (16.0) 
Creatinine kinase elevation 6.4 
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Functional disability  
The mean SHAQ score was 0.87 (SD 0.66). 59.5% of the patients were in the lowest SHAQ 
category (score of 0 to <1), 34.0% had a score of 1 to <2 and 6.5% were in the category regarded 
as ‘severe to very severe disability’ (score of 2 to 3). Patients fulfilling only the 2013 ACR/EULAR 
criteria but not the 1980 ACR criteria had a lower average SHAQ score (0.55, SD 0.56) than 
patients fulfilling the 1980 ACR classification criteria (0.91, SD 0.66; p<0.001). Patients with 
diffuse cutaneous SSc had a higher mean SHAQ score (0.96, SD 0.65), than patients with limited 
SSc (0.83, SD 0.67; p=0.005). 46.8% of patients with diffuse SSc had mild to severe disability 
(score 1 to 3) compared to 37.6% with limited SSc (p=0.003).  
The mean HAQ score was 0.92 (SD 0.78). 53.8% of patients fell into the ‘mild to moderate 
difficulty’ category (score <1), 34.1% into the ‘moderate to severe disability’ (score ≥1 to <2) 
and 12.1% into the ‘severe to very severe disability’ (score ≥2) category. Patients with diffuse 
SSc had a higher mean HAQ score than patients with limited SSc (1.04, SD 0.77 vs.  0.87, SD 
0.77; p=0.002).  
Of the five VASs included in the SHAQ, the highest values were reported on the overall disease 
severity VAS (mean 37mm, SD 27). Patients with diffuse SSc reported a higher level of limitation 
due to overall disease severity (mean 40mm, SD 27) than patients with limited SSc (mean 
35mm, SD 27; p=0.02).  
With respect to RP, the mean VAS impairment reported was 31mm (SD 28). Patients with 
diffuse SSc reported a higher level of impairment due to RP (mean 34mm, SD 29) than patients 
with limited SSc (mean 29mm, SD 27; p=0.01). 
The average perceived limitation due to pulmonary problems was 24mm (SD 27). Patients with 
diffuse SSc reported a similar level of impairment due to pulmonary symptoms (mean 24mm, 
SD 27) as patients with limited SSc (mean 24mm, SD 28; p=0.81). Patients in higher modified 
NYHA functional classes (as a proxy for dyspnoea, please see Table 8)  perceived a more marked 
pulmonary limitation than patients in modified NYHA-class I (modified NYHA-class IV, mean 
74mm, SD 24; modified NYHA-class III, mean 61mm, SD 24; modified NYHA-class II, mean 
29mm, SD 26; modified NYHA-class I, mean 11mm, SD 19; p<0.001).  
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With respect to gastrointestinal problems, patients reported a VAS average of 20mm (SD 26). 
There was no difference in the perceived impairment due to gastrointestinal problems between 
patients with diffuse SSc (mean 18mm, SD 25) and limited SSc (mean 21mm, SD 27; p=0.11). 
Patients with a higher number of simultaneous gastrointestinal symptoms reported higher 
average VAS scores than patients with a low number of gastrointestinal symptoms (42mm, SD 
31 for patients reporting all of oesophageal, gastric and intestinal symptoms; 26mm, SD 26 for 
patients reporting symptoms in two gastrointestinal regions; 16mm, SD 23 for patients 
reporting symptoms in only one gastrointestinal region; vs. 7mm, SD 14 for patients reporting 
no gastrointestinal symptom, respectively; p<0.001).  
The VAS assessing the impairment due to the presence of DU had relatively low scores (mean 
19mm, SD 28). Patients with diffuse SSc (mean 22mm; SD 30) reported a higher level of 
impairment than patients with limited SSc (mean 18mm, SD 27; p=0.02). However, patients 
who had DU prior to enrolment, but not at the time of SHAQ reporting, had a mean DU VAS of 
21mm (SD 28), and patients suffering from DUs at the time of SHAQ completion reported a 
mean VAS of 53mm (SD 33; p<0.001).  
 
Predictors of functional disability  
We first assessed the association of variables with the SHAQ with univariable analysis. The 
strongest predictor of disability was dyspnoea. In patients with modified NYHA class IV the 
SHAQ score was on average 1.17 units (95%CI 0.80-1.53) higher than in patients with modified 
NYHA class I (modified NYHA class III - 0.88, 95%CI 0.73-1.04 and modified NYHA class II - 0.40, 
95%CI 0.32-0.48 all vs. modified NYHA class I). Weaker, although still clinically important 
predictors were (in order of magnitude) muscle weakness (increase of 0.51 units, 95%CI 0.40-
0.62), the presence of fibromyalgia (increase of 0.47 units, 95%CI 0.25-0.69) and the three 
variables referring to gastrointestinal involvement (gastric 0.41 units, 95%CI 0.32-0.50; 
oesophageal 0.38 units, 95%CI 0.29-0.46 and intestinal symptoms 0.34 units, 95%CI 0.25-9.42).  
The multivariable analysis of the SHAQ was in line with the results observed in univariable 
analysis. Dyspnoea remained the strongest predictor of functional disability. The SHAQ scores 
reported by patients with modified NYHA class IV, III or II were on average 0.62 units, 0.53 units 
and 0.21 units higher than that of patients with modified NYHA class I (Figure 16). In addition, 
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both the presence of fibromyalgia as well as muscle weakness were associated with higher 
levels of disability. Patients with fibromyalgia reported on average a SHAQ value 0.37 units 
higher than that of patients without fibromyalgia, and patients experiencing muscle weakness 
recorded on average a 0.27 units higher SHAQ (Figure 16). Other factors contributing to 
disability included the presence of DUs, oesophageal, gastric and/or intestinal symptoms, joint 
contractures and a more severe skin involvement (Figure 16). Only dyspnoea, fibromyalgia and 
muscle weakness however remained clinically significant contributors to functional disability 
when applying the 0.22 threshold for the MCID [Wells et al., 1993].  
Patients experiencing any gastrointestinal involvement (presence of oesophageal, gastric or 
intestinal symptoms) reported a clinically significant higher SHAQ (0.24 units; 95%CI 0.15-0.32) 
than patients reporting no gastrointestinal involvement. In multivariable analysis, patients with 
multiple simultaneous gastrointestinal symptoms also had higher SHAQ scores than those 
featuring symptoms in only one or two regions of the gastrointestinal tract (oesophagus, 
stomach, or intestine). Patients reporting oesophageal, gastric and intestinal symptoms 
simultaneously had, on average, a SHAQ score of 0.46 units (95%CI 0.34-0.58) higher than 
patients reporting no gastrointestinal symptoms. Similarly, patients with symptoms in two or 
one gastrointestinal regions also reported a higher functional disability than patients with no 
gastrointestinal problems (0.28 units, 95%CI 0.18-0.38 and 0.13 units, 95% CI 0.04-0.22; 
respectively).  
The analysis of the HAQ scores showed impairment similar to the SHAQ. In univariable analysis 
in patients in modified NYHA functional class IV the HAQ was on average 1.32 units higher 
(95%CI 0.88-1.75) than in patients in modified NYHA class I; respective values for patients in 
modified NYHA class III were 0.96 units (95%CI 0.78-1.14) and in patients in modified NYHA 
class II 0.46 units (95%CI 0.37-0.56 all vs. modified NYHA I). Other factors associated with higher 
HAQ scores were (in order of magnitude): the presence of muscle weakness (0.59 units [95%CI 
0.46-0.72]), the presence of muscle atrophy (0.50 units [95%CI 0.30-0.70]), the presence of 
fibromyalgia (0.42 units [95%CI 0.16-0.67]), joint contractures (0.44 units [95%CI 0.35-0.54]), 
gastrointestinal symptoms (oesophageal-0.40 units, 95%CI 0.30-0.50; gastric-0.43 units, 95%CI 
0.32-0.54; intestinal-0.35 units, 95%CI 0.25-0.45) and tendon friction rubs (0.40 units [95%CI 
0.16-0.64]).  
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Figure 16. Predictors for the composite SHAQ and the HAQ scores in SSc patients. 
Multivariable regression coefficients with 95%CI for the composite SHAQ and the HAQ scores 
(both ranging from 0 to 3). Regression coefficients and their 95%CI are presented in bold writing 
if the 95%CIs do not include zero.  
Age, increase per 10 years; DLCO, increase per 10% of predicted; dyspnoea, modified NYHA 
functional classes II/III/IV vs. LVEF, increase per 10%; modified NYHA functional class I; ESR, 
increase per 10mm/hr; FVC, increase per 10% of predicted; mRSS, increase per 5 points; 
PAPsys, increase per 10mmHg; sex, female vs male; time since first non-RP, increase per 10 
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None of the objective clinical measures were associated with a higher SHAQ score (Figure 16). 
The changes in the average SHAQ scores were (in order of absolute magnitude): 10% higher 
LVEF (-0.05 units), 10mmHg higher PAPsys (0.04 units), presence of conduction blocks (-0.04 
units), presence of a diastolic dysfunction (-0.03 units), 10% of predicted FVC (-0.02 units), 10% 
of predicted lower DLCO/sb (-0.01 units) and the presence of pericardial effusion (-0.01 units). 
In multivariable analyses, patients with modified NYHA functional class IV had an average HAQ 
score of 0.70 units higher than patients with modified NYHA functional class I (modified NYHA 
class III - 0.54 units, modified NYHA class II - 0.23 units all vs. modified NYHA class I). The 
presence of fibromyalgia (increase of 0.33 units) as well as of muscle weakness (increase of 
0.32 units) were also strong and clinically important predictors of elevated HAQ scores (Figure 
16). The presence of any gastrointestinal problems, i.e. either the presence of oesophageal, 
stomach or intestinal symptoms, led to a clinically important average increase of 0.22 HAQ units 
(95%CI 0.11-0.31). Similarly, the number of simultaneous gastrointestinal symptoms was a 
strong predictor of an elevated HAQ; patients reporting each of oesophageal, gastric and 
intestinal symptoms, the average HAQ increase was 0.44 units (95%CI 0.30-0.58), for patients 
reporting symptoms in two gastrointestinal regions the average increase was 0.26 units (95%CI 
0.14-0.38) and for patients reporting symptoms in only one gastrointestinal region the HAQ 
increase was 0.11 units (95%CI 0.002-0.22) compared to patients reporting no gastrointestinal 
symptom.  
 
Disability in the SSc subsets 
In patients with diffuse SSc (n=344), the factors contributing to a clinically meaningful SHAQ 
increase were similar to those contributing in patients with limited SSc (n=532; Figure 17), 
namely dyspnoea (modified NYHA III/IV vs. modified NYHA I/II increase of 0.42 units), muscle 
weakness (increase of 0.36 units) and gastrointestinal symptoms (Figure 17). Patients with 
fibromyalgia also had on average a 0.25 units higher SHAQ (Figure 17).  
In both SSc subsets, the presence of multiple simultaneous gastrointestinal symptoms also 
strongly predicted disability. In patients with diffuse SSc, the SHAQ was on average 0.39 units 
(95%CI 0.19-0.59) higher in patients simultaneously reporting oesophageal, gastric and 
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intestinal symptoms than in patients not reporting gastrointestinal symptoms. In the group of 
patients with limited SSc, this difference was even greater (0.60 units (95%CI 0.44-0.78)). 
 
 
Figure 17. Predictors for the composite SHAQ in patients with diffuse and patients with 
limited cutaneous SSc. 
Demographic and disease characteristic as well as multivariable regression coefficients with 
95% CI for the composite SHAQ score (range 0 to 3) for patients with diffuse and limited 
cutaneous SSc. Regression coefficients and their 95%CI are presented in bold writing if the 
95%CIs do not include zero. 
Age, increase per 10 years; DLCO and FVC, increase per 10% of predicted; dyspnoea, modified 
NYHA functional class III/IV vs. modified NYHA functional class I/II; mRSS, increase per 5 points; 







Our study is by far the largest study linking patients’ self-assessed disability with objective 
clinical data and is also the first study of its size to analyse a comprehensive set of clinical factors 
contributing to disability in an SSc population not selected for a particular organ manifestation 
or subset. The physicians’ main attention while caring for SSc patients is often focused on 
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objective measures of function for example pulmonary function tests. These measures may 
however not reflect the patient’s experience with the disease, self-perceived impact on QoL 
and functional capacity.  
The most important factors predicting functional disability in our study were dyspnoea, 
gastrointestinal symptoms, fibromyalgia, muscle weakness and the presence of DU, in line with 
the results of smaller studies [Suarez-Almazor et al., 2007; Franck-Larsson et al., 2009; Omair 
et al., 2012; Guillevin et al., 2013; Lóránd et al., 2014; Brand et al., 2015; Lumetti et al., 2015]. 
Thus, there is a major difference between the factors driving patient perceived levels of 
disability and those emphasized by physicians (i.e. lung function testing, pulmonary arterial 
pressure estimates et cetera). In clinical practice though, objective quantifications of 
gastrointestinal symptoms, fibromyalgia, muscle weakness and DUs are rarely performed. 
Comparing the four specific VASs, the highest patient-rated limitation of daily life was due to 
RP, followed by pulmonary and gastrointestinal symptoms. A similar finding was observed in 
two surveys in which SSc patients ranked RP, gastrointestinal complications, musculoskeletal 
involvements and pain among the symptoms influencing their daily life the most [Bassel et al., 
2011; Frantz et al., 2016]. In contrast to our study, Strickland et al. [Strickland et al., 2012] only 
found an association between functional disability and gastrointestinal involvement, but not 
with any other demographic or clinical variable. Similarly, Chow et al. [Chow et al., 2008] did 
not detect a correlation between NYHA functional class, the strongest predicting factor in our 
study, and functional disability in SSc patients with pulmonary arterial hypertension. One likely 
reason for this discrepancy is the limited sample size of 68 and 41 patients, respectively. 
Additionally, in the study by Chow et al. [Chow et al., 2008] the selection of patients might be 
another likely reason as the investigators only included SSc patients with pulmonary arterial 
hypertension and dyspnoea resulting in a distribution of NYHA classes skewed towards the 
higher classes.  
The overall level of disability as identified by the HAQ in our European SSc population is more 
than 4 times higher than that reported in the general French population, and comparable with 
that reported in other systemic rheumatic diseases [Johnson et al., 2006; Loos-Ayav et al., 2007; 
Oude Voshaar et al., 2014]. The HAQ score observed in our cohort is similar to that found in 
other SSc studies, with about half of patients considering themselves to be mildly to moderately 
disabled [Strickland et al., 2012; Racine et al., 2016]. However, the SHAQ scores as well as the 
DESSCIPHERING SYSTEMIC SCLEROSIS 
- 115 - 
VASs encompassed in it are lower in our study than in a French single-centre study [Georges et 
al., 2005]. This discordance might be explained by the lower percentage of diffuse SSc patients 
in our population.  
In patients with diffuse SSc, the level of disability was significantly higher than in patients with 
limited SSc. The differences between SSc subsets in our cohort were however smaller than 
those reported previously in much smaller studies [Smyth et al., 2003; Georges et al., 2005; 
Strickland et al., 2012]. Interestingly, the main factors contributing to disability, namely 
dyspnoea, gastrointestinal symptoms, muscle weakness, DUs and pain, were similar in the SSc 
subsets. This goes in line with a recent survey by Frantz et al [Frantz et al., 2016] which 
identified no difference of patient perceived impact of organ involvement on QoL between SSc 
subsets.  
There are limitations of our study. We only had SHAQ data of about 45% of all eligible patients. 
A selection bias might have occurred in both directions, i.e. patients with more severe disease 
may have felt too unwell to fill in the SHAQ questionnaire, or were actually more likely to fill in 
the questionnaire, as they felt more impaired. The demographic characteristics of the patients 
included in this study were however comparable to the DeSScipher patients without an 
available SHAQ, as were the disease duration and the distribution of the SSc subsets. One 
problem often arising in observational studies is the data quality. However, one big strength of 
the DeSScipher cohort is that there were various strategies in place to enhance data quality, 
including on-site data monitoring. Thus, our results are likely to better reflect the bigger SSc 
community than those of previous studies, particularly due to the multi-centre and 
multinational nature of this study.  
In conclusion, this study demonstrates significantly impaired functional capacity in a large 
proportion of SSc patients, and demonstrates that dyspnoea, pain, DUs, muscle weakness and 
gastrointestinal symptoms are the most important contributors perceived by the patients. Our 
finding that objective measures are not associated with patient perceived disability is a clarion 
call to researchers and clinicians that the many and multi-faceted aetiologies of disability in SSc 
are poorly understood.  Further, the root causes impacting disability are likely overlooked and 
poorly assessed in the clinical setting, As a result of this, QoL is not yet targeted by our 
treatment armamentarium.   
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7. DISCUSSION, CONCLUSION AND OUTLOOK 
7.1. SUMMARY OF MAIN FINDINGS 
This thesis sheds light on the timing of SSc specific organ manifestations and risk factors for 
speedier onsets, the effect of the modifiable risk factor, smoking, on organ manifestations and 
factors that the patients perceive as most burdensome. The main findings of this thesis are 
summarised below. 
 
Aim 1 - Organ Involvement, when does it start? 
This longitudinal study uniquely mapped the incidence of skin and organ manifestations in early 
SSc patients and detailed differences in the evolution of disease manifestations. The main 
findings are that early after the onset of RP, organ manifestations exhibit rapid kinetics in SSc. 
Most patients experience the maximal gain of skin sclerosis within one year after the onset of 
RP and diffuse cutaneous involvement emerges newly in only a minority of patients after five 
years of disease onset. In every internal organ system, half of all organ manifestations are 
evident within the first two years. The disease onset follows a simultaneous rather than 
sequential manifestation pattern, i.e., the steep increase in manifestations during the first years 
is persistently observed across the studied organ complications. Even the severe complications, 
for instance, PH and ILD, are not restricted to late disease contrasting the experienced-based 
knowledge about the timing of manifestation until now (Figure 2 [Varga et al., 2012]).  
The different risk factors for the occurrence of the various organ manifestations modify the 
cumulative incidences of the organ manifestations. However, these do not substantially modify 
the steep increase in manifestation rates during the first two years after RP onset. For example, 
the risk factors governing the extent and severity of skin involvement (e.g., male sex and 
autoantibody status associated with the development of diffuse disease) do not influence the 
disease kinetics, e.g., the time to mRSS peaking.  
The main finding that early after the onset of RP, organ manifestations exhibit rapid kinetics in 
SSc, implies that there is only a short ‘window of opportunity’ to prevent incident organ 
damage. By mapping the temporal evolution of SSc specific manifestations and identifying risk 
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factors early during the disease course, this study will enable physicians to more accurately 
counsel SSc patients presenting early in their disease. These findings also have implications for 
the design of new diagnostic strategies and therapeutics aimed to ‘widen’ the still very narrow 
‘window of opportunity’. 
 
Aim 2 - Smoking, does it make it worse? 
This study assessed possible associations of smoking exposure and smoking intensity with organ 
manifestations and their level of worsening. It goes beyond those already published not only 
by the number of patients included, but also by applying three different smoking models 
leading to greater robustness of the results. We found that the known adverse effects of 
smoking on bronchial airways and alveoli are also observed in SSc patients. The main finding is, 
however, that there are no robust adverse effects of smoking on the progression of SSc-specific 
pulmonary or cutaneous manifestations.  
We also found a lower prevalence of anti-Scl-70 autoantibodies in current smokers. This 
imbalance was also seen in another publication [Chaudhary et al., 2011] and raises the question 
of a possible aetiopathological link between smoking and anti-Scl-70 positivity. 
The findings of this study argue against a major role of tobacco-associated free radicals, 
vasoconstrictory and immunomodulatory effects in the pathogenesis of SSc vasculopathy and 
fibrosis. The results are of importance firstly to clinicians who counsel and manage SSc patients, 
but also to the patients themselves wondering about the effect of the modifiable risk factor 
smoking on their disease outcome.  
 
Aim 3 - Physical function, the patient perspective. 
The physician’s main attention while caring for SSc patients is often focused on objective 
measures of function. These measures, however, may not reflect the patients’ experiences with 
the disease and their self-perceived impact on their functional abilities. Therefore, this study 
assessed functional disability and identified factors contributing to functional impairment. The 
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main finding is that there is a major difference between the factors driving patient perceived 
levels of disability and those emphasized by physicians in the evaluation of their disease.  
Patients perceive dyspnoea, GI symptoms, pain, muscle weakness and the presence of DUs as 
the main factors driving their level of disability. In clinical practice though, objective 
quantifications of GI symptoms, fibromyalgia, and muscle weakness are rarely performed, and 
therefore the causes influencing disability are likely overlooked and poorly assessed in the 
clinical setting. Moreover, as a result of this, QoL and functional ability are not targeted by the 
current treatment armamentarium. This study found that objective measures are not 
associated with patient-perceived disability and, is, therefore, a clarion call to researchers and 
clinicians that the many and multi-faceted aetiologies of disability in SSc are poorly understood. 
 
 
7.2. STRENGTH AND LIMITATIONS 
The greatest strengths of all four studies are their large sample sizes, the multinational nature, 
and their unselected patient populations, i.e., their registry-based design. At the same time, 
this great strength, i.e., the registry-based set-up, also poses certain limitations. As in almost all 
registries, data completeness and data quality are also issues within the EUSTAR/DeSScipher 
registry. However, various strategies are in place to minimise these problems. Plausibility, 
validity, range, and presence checks to improve data quality and to a certain extent also data 
completeness were already implemented into the EUSTAR registry from the beginning of the 
online data collection. These were greatly extended during the DeSScipher do-over of the 
database as extensive checks at the data entry level are among the most essential tools to 
improve data quality in almost all data collection systems especially in registries [Silver et al., 
2006; Gliklich et al., 2014]. Additionally, at DeSScipher centres on-site as well as off-site 
monitoring with source data verification took place to enhance the quality of data as well as 
their completeness further.  
Another problem is the data reliability of the more ´subjective` measures such as the skin 
scoring for the mRSS. Reliable data on the level of skin involvement is especially important in 
SSc, firstly as it is a hallmark feature of the disease and secondly as it is an outcome measure of 
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two of the three main aims of this project. As the mRSS has a high intra-person variability, the 
centres were encouraged to always have the same physician carry out the skin scoring 
[Clements et al., 1995]. Additionally, EUSTAR offered repeated mRSS training courses to 
instruct the physicians, and there was also a training video available for physician who had not 
undergone one of the training courses to minimise the variability of the skin scoring [Czirják et 
al., 2007].  
There are also potential study-specific limitations. In the first two studies assessing the speed 
of organ manifestation onset, some SSc patients had documented organ complications already 
at their baseline visit. In this case, we did not know the exact onset of the complication leading 
to an overestimation of the time to its onset. However, the longest possible overestimation is 
one year, as we restricted the patient population to those patients with a baseline visit within 
one year after the disease onset.  
In the smoking study, the information on the smoking status and the smoking intensity was 
provided by the patients, and we had no means to verify this information. We were, however, 
able to demonstrate the known adverse effects of smoking, suggesting that the information 
provided by the patients was not random. A major strength of this study was also the utilisation 
of three smoking models assessing both the smoking behaviour and the smoking intensity as 
well as additionally the CSI of patients. Especially the use of the CSI incorporating smoking 
duration, time since smoking cessation and the smoking intensity into one score added to the 
robustness and the validity of the results. 
  
7.3. GENERALISABILITY OF FINDINGS 
The EUSTAR/DeSScipher patient population, per se, is an unselected cohort of patients, and 
therefore results are generalizable to SSc patients. However, we applied some restrictions to 
the populations we studied, either ́ actively` by restricting the population to patients presenting 
early after disease onset (Aim 1) or patients with a follow-up in the required time frame (Aim 
2) or ´passively` by just including patients with available data for the outcome measures of 
interest (Aims 2 and 3). 
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By restricting the included patients to patients presenting early after disease onset, we 
introduced a selection bias as evidenced by the high prevalence of male and anti-Scl-70 positive 
patients and also by their higher age of onset in those patients included in the study. These 
factors are known to be associated with more severe disease and adverse outcomes in SSc 
[Perera et al., 2007; Walker et al., 2007; Graf et al., 2012; Nihtyanova et al., 2014; Elhai et al., 
2016]. Hence, the generalizability to the entire SSc population is questionable. Nevertheless, 
more than half of all EUSTAR patients (i.e., the entire EUSTAR cohort) experienced their first 
non-RP feature of the disease within one year of the onset of RP (Figure 11). Therefore, the 
results are still generalizable to a rather high percentage of SSc patients. 
In the smoking study (Aim 2), we only included patients with a follow-up visit. We are aware 
that this decision yields the risk of an informative drop-out whereby we might have excluded 
the sickest patients who might be most likely to have worsening disease and therefore enriched 
the studied population with ´healthier` patients or vice versa enriching for ´sicker` patients. 
However, we did compare the demographics and the disease characteristics of the patients 
excluded due to the absence of a follow-up visit to the included patients (Supplementary Table 
6), and we did not see any major differences. Therefore, we did not exclude the sickest nor the 
healthiest patients by this inclusion criterion.  
We also did not have smoking data on almost half of the adult EUSTAR SSc patients. Most of 
the missing data on smoking behaviour (around 98%) are purely a design issue as the smoking 
module was only introduced into EUSTAR in 2013. Therefore, those patients who were not 
included in the study due to the ´missing smoking data by design ` will be ´missing completely 
at random (MCAR)` and will not introduce a bias. Both points above do argue against a major 
selection bias, and therefore the results are generalizable to the entire SSc patient population. 
Similarly, to the above inclusion criterion, we did the same for the functional disability study 
(Aim 3) where we only included patients who filled in the PRO questionnaire (around 45% of all 
eligible patients). The possible selection bias arising from this might have gone in both 
directions. Patients with severe disease might have been more likely to fill in the SHAQ 
questionnaire, as they felt more impaired. On the other hand, they might have been less likely 
as they were too unwell to fill in the PRO. Both scenarios would bias the results in different 
directions. However, from our experience and communications with other centres, the low 
´compliance` was a mix of:  
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(1) the investigators not asking the patients to fill the SHAQs for various reasons (not 
enough time during clinic visits, being critical about PROs, just forgetting it, etc.) and  
(2) patients not filling in the questionnaire also for various reasons (not wanting to fill in 
anything, just forgetting to do so, forgetting to return it, etc.).  
Additionally, the demographic characteristics and the distribution of the SSc subsets of the 
patients included in the functional disability study were comparable to the patients without 
information on their functional ability. Therefore, we believe that this selection did not 
introduce a major bias and that the results are valid for unselected SSc populations. 
 
7.4. CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
A main clinical implication of these studies is that SSc patients need to be diagnosed early after 
disease onset, risk stratified and followed tightly with planned controls. This is important, 
especially early on in the disease, to ´catch` internal organ involvement in its incident stages, 
and because the more severe, potentially life-threatening complications of the disease are not 
limited to later disease. Additionally, awareness needs to be raised and improved among 
physicians for early referral of SSc patients or patients suspected to suffer from SSc to centres 
specialised in SSc care allowing to use the narrow ‘window of opportunity` effectively as more 
than half of all organ complications manifest within the first two years of the disease. These 
results also enable the treating physicians to counsel and manage patients presenting early in 
the course of SSc more accurately regarding the expected speed of onset of organ 
manifestations and also to ´risk stratify` the patients for example according to their sex and 
autoantibody profile. 
One factor that we did not include in the studies was the patients' race. It is known, that African 
Americans have a younger age at disease onset, have a more severe disease and greater 
mortality. Data, however, mostly stem from African Americans. Studies on the disease 
presentation and severity on Africans and especially Asians are sparse. In collaboration with 
EUSTAR and the EUSTAR centres in Johannesburg, South Africa, and Beijing, China, we recently 
initiated a study looking at differences in disease presentation and severity in these patient 
groups. This will help to ´risk stratify` patients even further. 
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The results that objective disease severity measures as assessed by the physicians do not 
correlate with patient-perceived disability, actually raise more questions than they provide firm 
answers; questions which should be essential to research priorities and the development of 
targeted strategies in clinical care. They indicate that both perspectives, the physicians' and the 
patients', should be taken into account as complementary and that the possible communication 
gaps between physicians and patients should be closed. The results are also a clarion call to 
researchers and clinicians by indicating that the many and multi-faced aetiologies of disability 
and QoL in SSc are poorly understood. Furthermore, the root causes impacting disability are 
likely overlooked and poorly assessed in the clinical setting and, as a result of this lack of 
knowledge, management strategies are not yet part of the treatment armamentarium. Aspects 
of QoL and disability are plentiful, everyday occurrences, making them more ´ordinary` and 
therefore easily overlooked opportunities to make it easier for the patient to live with the 
disease, in comparison to the anticipation of breath-taking novel drugs. 
Current medical treatment of SSc patients is frustrated by the mediocre response of the 
disease. While the ultimate goal must be a low-risk curative therapy, people continue to live 
and die with the complex disease and with the heavy symptom burden of SSc. One of the high 
impacts clinicians and researchers might have in a patient’s health status in the next decade is 
to decipher and strategically address the barriers to function and quality of life, and potentially, 
survival. 
To partially address this, we started a follow-up study focusing on the change in levels of 
functional ability over time and factors associated with an improvement as well as with 
worsening. Additionally, we would like to identify groups of patients with similar trajectories of 
functional ability over time and factors defining them to be able to put more emphasis on these 
factors, raise awareness, and hopefully treat them to help people living with SSc in their 
everyday life. We also aim to evaluate if changes in functional ability are associated with 
simultaneous worsening of organ manifestations, which also would enable the patients to be 
more involved in their disease management. 
Research has tremendously increased the knowledge about SSc in the last decades, but it has 
not come far enough yet. Neither the exact cause of SSc nor all factors triggering disease onset 
and progression have been identified yet. Therefore, broad research is still required from basic, 
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translational and pharmaceutical partners, but also from large international cohorts and 
collaborations.  
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EXPLANATION OF THE TITLE 
The skin and its thickness 
The registry and its data 
The star and the sunflower 
- 
Bringing it all together 
- 
DeSSciphering Systemic Sclerosis 
 
The title of this thesis can be broken down into its parts each referring to a component of this 
thesis.   
- ´the skin and its thickness` refers to the disease under study, systemic sclerosis. 
- ´the registry and its data, the star and the sunflower` refers to registry in which the 
data used in this thesis was collected, the European Scleroderma Trials and Research 
registry (EUSTAR). The ´star` refers to the logo of the EUSTAR registry which originates 
from a painting by Paul Klee who died of systemic sclerosis. The ´sunflower` refers to 
the logo of the DeSScipher project.  
- ´bringing it all together` refers to the data analysis without which no results would be 
obtained. 
- ´DeSSciphering systemic sclerosis` refers to the results presented in this thesis while 
being a play on words with the DeSScipher project. 
 
